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Abstract
PREDICTING MEDICATION ADHERENCE PATTERNS DURING THE MAINTENANCE
PHASE OF TREATMENT FOR PEDIATRIC LEUKEMIA AND LYMPHOMA: A MODEL
OF INDIVIDUAL- AND FAMILY-LEVEL FACTORS
By Stephanie Romo, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2022
Co-Chairs:
Jennifer Rohan, Ph.D.
Assistant Professor
Division of Pediatric Hematology-Oncology and Stem Cell Transplantation
and
Rosalie Corona, Ph.D.
Professor
Department of Psychology
Adherence during the maintenance phase of pediatric cancer treatment is critical to
prevent relapse and ensure long-term, event-free survival. Yet, little research has been done to
examine individual- and family-level factors that may relate to adherence during the maintenance
phase of treatment, particularly among Latinx patients. This is surprising given findings
demonstrating that children who miss more than 5% of their prescribed oral chemotherapy
medicine, most commonly 6-mercaptopurine (6MP), are 2.5-2.7 times more likely to relapse than
children who take 95% or more of their prescribed 6MP. Pediatric cancer patients face unique
adherence challenges given the importance of family involvement in children’s care. As such, it
is important to consider both individual- and family-level factors when examining adherence.
Objective. Conducted a secondary data analysis to investigate individual- and family-level
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factors that may predict 6MP medication adherence patterns, in a multisite cohort of pediatric
patients diagnosed with acute lymphoblastic leukemia (ALL) or lymphoblastic leukemia (LBL),
in a sample that is 34% Latinx. Methods. Participants included 139 patients ages 7-19 years
diagnosed with ALL or LBL, across six centers. Medication adherence was measured daily for
15 months using electronic monitoring of 6MP. At baseline, 6 months, and 15 months,
participants reported on individual- (e.g., child depressive symptoms, caregiver depressive
symptoms, child/adolescent health beliefs) and family-level (e.g., caregiver-child communication,
younger children within the home) factors that might predict adherence patterns. Medical history
was evaluated via standardized medical chart reviews at baseline, 6 months, 15 months, which
included information on prescribed daily 6MP dose and duration of cancer diagnosis. Results.
Results demonstrated characteristic differences between the adherence groups (e.g., age, dose,
health beliefs). Results further indicated that developmental age group was the strongest predictor
of medication adherence, such that youth in the middle-late adolescence age group were
significantly more likely to be in the nonadherent group than youth in the preadolescent or earlymiddle adolescence age groups. Dosage and health beliefs, specifically positive outcome
expectancy, also significantly predicted adherence group membership. Preliminary exploratory
analyses indicate that predictors of adherence may differ between Latinx and non-Latinx, white
patients. These results must be interpreted cautiously as the current study focused on outcomes
rather than processes and social stratification. Furthermore, exploratory analyses indicated that
adherence and quality of life were not significantly related in the current study, in either direction.
Conclusions. Older adolescents may be at increased risk for nonadherence, which is an area of
major concern warranting future research in this area. Findings also indicate that fostering
positive outcome expectancy among youth at the start of maintenance phase may serve to enhance
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adherence during this phase of treatment. Future work examining adherence behaviors should
continue to assess longitudinal individual, family, and medication-level factors.
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Introduction
Childhood Cancer: Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Advancements in treatment for pediatric cancer over the last five decades has resulted in
significant improvements in survival. Overall survival rates for childhood cancer have increased
from 58% in 1975 to over 85% in 2020 (Howlader et al., 2020; Jemal et al., 2013). While
survival rates continue to vary by cancer type (Howlader et al., 2020), increases in overall
survival rates are largely attributed to participation in clinical trials that investigate efficacy and
side effects of multimodal cancer treatments (G. T. Armstrong et al., 2016; Brennan et al., 2010;
Hudson et al., 2012). Despite these critical improvements in care, cancer remains the secondleading cause of death among youth (Heron, 2019). It is estimated that approximately 1,050
children and 550 adolescents will die from cancer in 2022 (American Cancer Society, 2022;
Siegel et al., 2021).
Leukemias are the most common childhood cancers with the most common being acute
lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). These cancers of the bone
marrow and blood account for roughly 28% of all cancers diagnosed in childhood (American
Cancer Society, 2019). Brain and spinal cord tumors are the second most common cancers in
children, making up about 26% of childhood cancers (American Cancer Society, 2019). Hodgkin
and Non-Hodgkin Lymphomas, cancers of the lymphatic system, are the third most common
cancers diagnosed in children (National Cancer Institute, 2020). Lymphoblastic lymphoma
(LBL), which is treated similarly to ALL, primarily affects children and accounts for 25% to
30% of all non-Hodgkin lymphomas in children (American Cancer Society, 2016).
While there is ongoing debate concerning whether LBL and ALL are two presentations
of the same disease or two distinct diseases, they are commonly considered to be part of a
spectrum of malignant lymphoproliferative disorders (Kelly et al., 2018; Reddy & Perkins,
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2004). The cancer cells of both ALL and LBL are very young lymphocytes called lymphoblasts
(Kelly et al., 2018). Patients with ALL present with at least 25% of their bone marrow made up
of lymphoblasts, whereas patients with LBL present with a mass and less than 25% bone marrow
lymphoblasts (American Cancer Society, 2016). Similarities in morphology, genetics, and
immunophenotypes have resulted in patients with ALL and LBL being treated on similar
treatment protocols (Cortelazzo et al., 2017; Reiter et al., 2000; Weiss et al., 1986).
While specific treatment protocols for both ALL and LBL can differ based on staging
results (e.g., cancer phenotype, genotype, and risk), treatment protocols consistently involve an
intensive phase of cancer treatment followed by a maintenance phase (Asselin et al., 2011; Lau
et al., 1998; Pui & Evans, 2006; Reiter et al., 2000). The duration of the intensive phase can
range from several months to one year depending on diagnosis, sex, age, response to treatment,
and clinical severity (Cortelazzo et al., 2017; Lau et al., 1998; Pai et al., 2008). This intensive
phase of cancer treatment typically involves extensive inpatient admissions; four or five
medications administered in clinic and during hospitalizations, most of which are administered
intravenously; and in some cases, at-home nursing care visits following hospital discharge
(Colby-Graham & Chordas, 2003; Pui & Evans, 2006).
The maintenance phase, also referred to as continuation treatment, begins once a patient’s
ALL or LBL is in remission. The primary goals of the maintenance phase of chemotherapy are to
eliminate any residual cancer and prevent disease relapse. The maintenance phase of treatment
can last for 2-3 years and involves multiple medications given on an outpatient basis (Cortelazzo
et al., 2017; Lau et al., 1998; Pui & Evans, 2006). Maintenance therapy is considered vital for
long-term, relapse-free survival for pediatric patients diagnosed with ALL and LBL (Bhatia et
al., 2012, 2014, 2015; Kennard et al., 2004; Pritchard et al., 2006).
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The maintenance phase necessitates that patients adhere to a long and complex course of
treatment (Butow et al., 2010; Kazak et al., 2010; Malbasa et al., 2007; Wu et al., 2018).
Throughout maintenance, patients are prescribed several oral medications, some of which are
required daily (e.g., oral chemotherapy), weekly (e.g., methotrexate), and monthly (e.g., 5 day
course of corticosteroids; Davies & Lilleyman, 1995; Landier, 2011). In addition to these
scheduled oral medications, patients take other medications as needed (e.g., pain medication,
vitamin D), attend monthly medical follow-ups, and receive monthly injections of vincristine
(Kondryn et al., 2011; Malbasa et al., 2007; Pai et al., 2008). A daily dose of oral chemotherapy
medication, most commonly 6-mercaptopurine (6MP), is a key element of ALL and LBL
treatments often ranging between 550 to 1200 doses over the course of maintenance treatment.
6MP is most commonly administered in pill form and is only available in 50mg tablets. This
complex and multifaceted treatment can be very challenging for children, adolescents, and their
families (Kondryn et al., 2011; Malbasa et al., 2007; Pai et al., 2008; Pritchard et al., 2006; Wu et
al., 2018), ultimately affecting their adherence to treatment recommendations.
Scope, Prevalence, and Impact of Medical Nonadherence
The World Health Organization (WHO), defines adherence as the ability for a patient to
take medication as prescribed by a health care provider (WHO, 2003a). When describing patient
health behaviors, the term “adherence” is preferred to the term “compliance” (Haynes, 1979;
Verma & Rohan, 2020), as the term adherence reduces the implicit reference to the authority or
power healthcare providers hold over a patient’s health behaviors (i.e., “you must do what I say”)
and acknowledges the important role of the patient in their own treatment (i.e.., “we both have a
part to play in your treatment journey”; Kyngäs, Duffy, et al., 2000; Santer et al., 2014; Verma &
Rohan, 2020). Adherence can be differentiated from “concordance,” which emphasizes a shared
decision among equal partners in a therapeutic alliance (Drotar & Rohan, 2014; Horne, 2006).
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However, some recommendations, such as medication treatment regimens, cannot be shared
decisions given that patients must follow prescribed treatment regimens reasonably closely to
what is recommended to achieve the full benefits of a medication regimen (Osterberg &
Blaschke, 2005).
Nonadherence to medical treatments is defined as not completing a treatment regimen as
prescribed or recommended by a health care provider (Cortina et al., 2013; Osterberg & Blaschke,
2005; Rapoff, 2010; Rohan et al., 2017). Across pediatric chronic illnesses, nonadherence to
prescribed treatment regimens is a significant concern, with nonadherence prevalence rates
estimated at 50% or greater among children (Rapoff, 2010; World Health Organization, 2003b)
and ranging between 21-63% among adolescents (Butow et al., 2010; Hommel et al., 2009;
Kondryn et al., 2011; McGrady & Hommel, 2013). Consequences of nonadherence across chronic
illness populations include: increased symptoms, disease relapse, drug resistance, worse treatment
outcomes, increased morbidity and mortality, lower health related quality of life, and increased
health care utilization (Bae et al., 2011; Cortina et al., 2013; Drotar & Rohan, 2014; Kennard et
al., 2004; McGrady & Hommel, 2013; Osterberg & Blaschke, 2005; Pai & Drotar, 2010; Rapoff,
2010; Rohan et al., 2010; Verma & Rohan, 2020; World Health Organization, 2003b). Past work
has highlighted that as pill burden (i.e., number of pills taken daily) increases, adherence typically
decreases (Schlatter et al., 2016; Silverstein et al., 2014). Furthermore, current literature indicates
that adherence rates are typically higher among patients prescribed medication for short-term,
acute conditions, and lower for patients whose chronic conditions require long term medication
management (Kondryn et al., 2011).
The importance of consistent treatment adherence in the health outcomes of patients with
ALL and LBL is underscored in the literature. Nonadherence to cancer treatment is known to
impact morbidity and mortality in pediatric patients (Bhatia et al., 2012, 2014; Lau et al., 1998).

12

Treatment nonadherence may be related to clinical outcomes, such as worse disease prognosis,
and increased risk of adverse side effects, disease relapse, late effects of chemotherapy treatment,
and mortality (Bhatia et al., 2012, 2014, 2015; Davies & Lilleyman, 1995). Furthermore,
research indicates that treatment nonadherence may impact clinical biomarkers (e.g., neutrophil
counts and white blood cell counts), which provide information related to a child’s ability to
fight infections and influence chemotherapy dosing decisions (Bhatia et al., 2015; Haddy et al.,
1999; Lau et al., 1998; Lennard et al., 1993; Rivera et al., 2003; Schmiegelow et al., 2014).
Dosing titration decisions are largely based on a child’s absolute neutrophil count. Given that
appropriate dosing of 6MP is critical to achieve optimal medical outcomes and survival,
nonadherence to 6MP is cause for major concern (Malbasa et al., 2007).
The current literature elucidates that nonadherence to prescription medication, including
6MP, during the maintenance phase of treatment is common in children and adolescents
diagnosed with cancer (Bhatia et al., 2014, 2015; Davies & Lilleyman, 1995; Kondryn et al.,
2011; Lau et al., 1998; Psihogios et al., 2021; Rohan, Drotar, et al., 2015). Forty-four percent of
youth enrolled in a large Children’s Oncology Group (COG) study were identified as nonadherent
over the six month study period (Bhatia et al., 2012). Moreover, this research group reported that
47% of the relapses observed in the COG cohort were attributable to nonadherence (Bhatia et al.,
2012). Additionally, this research group established 95% adherence to 6MP during maintenance
phase as a critical cut-off level associated with a decreased risk of relapse (Bhatia et al., 2012,
2015). Specifically, youth who missed more than 5% of their prescribed oral chemotherapy doses
were 2.5 to 2.7 times more likely to relapse than youth who were at least 95% adherent to 6MP
(Bhatia et al., 2012, 2015). Given the significant impact of nonadherence to 6MP and other oral
chemotherapies, the accurate identification of patients struggling with adherence is crucial to
facilitate targeted interventions and support.
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Measurement of Adherence to 6-Mercaptopurine Medication in Pediatric ALL and LBL
Nonadherence can vary from the occasional missed dose to complete refusal (Bhatia et al.,
2014; Rapoff, 2010; Rohan & Winter, 2021; Verma & Rohan, 2020). Accordingly, it is critical to
utilize methods that capture granular levels of adherence behaviors. Systematic and reliable
objective measurement of treatment adherence in pediatric chronic illness is necessary, as findings
demonstrate that medical providers are often unable to accurately detect nonadherence using
subjective methods (Morisky et al., 1986; Pruette et al., 2019; Wagner et al., 2001). Patient and
caregiver reports also routinely overestimate adherence levels (Kenna et al., 2005; Landier et al.,
2017; Lau et al., 1998; Wagner et al., 2001) and often do not align with objective monitoring data
(Pruette et al., 2019). Kenna and colleagues (2005) suggest that adherence measures be
considered in two categories: 1) direct measures, such as observation of medication ingestion or
biological assays; and 2) indirect measures, such as patient-/caregiver-report (subjective),
prescription monitoring (objective), pill count (objective), or electronic monitoring (objective). A
wide range of adherence measures are accessible; however, each is subject to their own strengths
and limitations with biological assays and electronic monitoring often being considered the gold
standard for assessing adherence (Drotar & Rohan, 2014; Kondryn et al., 2011; Wu et al., 2013).
Many studies investigating adherence to medication regimens in pediatric ALL and LBL,
have relied on physician-, patient-, or caregiver- reported adherence (Kondryn et al., 2011;
McGrady & Pai, 2019). However, as noted above, person-reported adherence is often inaccurate
and, consequently, not ideal for accurately capturing and targeting nonadherence. Similarly,
measuring adherence via pill counts often leads to overestimations of adherence rates and lacks
objective data such as date and time medication was administered (Kenna et al., 2005).
Conversely, while electronic monitoring data provides information regarding the date and time
the medication cap was opened (Kenna et al., 2005; Vrijens et al., 2005), it does not directly
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assess ingestion. Moreover, research has found that patients might occasionally open the bottle or
remove medication from the bottle, but not actually ingest the medication (Cain et al., 2020;
Kenna et al., 2005; Lau et al., 1998; Psihogios et al., 2021). Direct measures such as biological
assays often provide the most reliable information about medication adherence; however, these
measures are costly, sometimes impractical, and do not provide information about the underlying
causes or patterns of nonadherence (Butow et al., 2010; Cain et al., 2020). Thus, Kenna and
colleagues (2005) suggest utilizing multiple methods of adherence measures when possible. Using
a combination of direct and indirect objective adherence measures can also provide validation of
clinical findings, offering more insight into what specific areas patients are struggling with most,
which can better inform adherence promotion interventions (Cortina et al., 2013; Rohan et al.,
2017; Rohan & Winter, 2021).
Limitations in Previous Research
While past work investigating medication adherence in the maintenance phase has been
conducted, they are not without limitations. First, the generalizability of previous work is limited
due to small sample sizes (e.g., N = 18 to 68), collection of data from a single site (Buchanan et
al., 2014; Davies & Lilleyman, 1995; McGrady & Pai, 2019; Partridge et al., 2002; Pritchard et
al., 2006; Ruddy et al., 2009), and lack of representation of minoritized ethnic groups. Particularly
underrepresented are Latinx patients. To our knowledge, only three studies examining adherence
during the maintenance phase have recruited a 10% or greater Latinx sample and reported on
findings specific to Latinx children (Bhatia et al., 2012; Landier et al., 2017; Rohan et al., 2015).
This is surprising given that the Latinx population accounted for 16% of the U.S. population in
2010 and 19% in 2020 (N. Jones et al., 2021) and that Latinx pediatric cancer patients are known
to have higher rates of disease relapse and mortality (Bhatia et al., 2002; Kadan-Lottick et al.,
2003; Milam et al., 2015). Second, previous research has typically relied on provider- or self-

15

reported adherence measures, which are known to overestimate adherence levels, and few have
used combination of direct and indirect objective adherence measures (Kondryn et al., 2011; Lau
et al., 1998; McGrady & Pai, 2019). Third, much of the research investigating medication
adherence among pediatric patients with ALL and LBL has been cross-sectional or time-limited
(e.g., a few weeks to a month), which restricts our understanding of adherence over the course of
the maintenance phase (Hawwa et al., 2009; Kondryn et al., 2011; Lau et al., 1998; McGrady &
Pai, 2019).
To date, eight studies have enrolled relatively large samples (N = 139 to 900) across
multiple sites (Bhatia et al., 2012, 2014, 2015; Kato et al., 2008; Lennard et al., 1995; Rohan et
al., 2017; Rohan, Drotar, et al., 2015; Wu et al., 2018). The duration of these larger studies ranged
from 1 month to 2.5 years. Adherence rates were established via medication refill analysis (Wu et
al., 2018), electronic monitoring (Bhatia et al., 2012, 2014, 2015; Rohan, Drotar, et al., 2015),
biological assays (Lennard et al., 1995; Traore et al., 2006), a combination of self-reported
adherence data and metabolite levels (Hawwa et al., 2009) and a combination of electronic
monitoring and assay data (Kato et al., 2008; Rohan et al., 2017). Among the studies utilizing
these data to evaluate adherence over time, the majority identified patients who were adherent or
not adherent using dichotomous metrics and few explored subgroups of children with different
trajectories of adherence over time.
To our knowledge, only one study has utilized latent group-based trajectory modeling to
identify patterns of nonadherence to 6MP during the maintenance phase (Rohan, Drotar, et al.,
2015). Rohan et al. (2015) examined linear trajectories of adherence across one-month and
identified three mutually exclusive adherence patterns: (1) optimal adherence (e.g., nearly 100%
adherence across time), (2) deteriorating/moderate adherence (e.g., decrease from 100% to 60%
adherence over time), and (3) chronic nonadherence (e.g., approximately 40% adherence over
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time). Furthermore, within these larger, longitudinal studies the relationship between medication
adherence and individual- and family-level factors were not explored. For instance, it is possible
that different individual- and family-level factors may predict medication adherence.
Understanding patterns of adherence and how individual- and family-level factors influence
adherence over time is essential to the development of innovative patient- and family-centered
interventions to minimize adherence barriers, identify much-needed resources for continued
success, and to maximize facilitators to adherence, which will ultimately improve outcomes.
Factors Associated with Adherence in the Maintenance Phase of Pediatric Cancer
Treatment
Adherence to 6MP in the maintenance phase is multifaceted and influenced by several
factors. As noted above, much of the work examining adherence in the maintenance phase of
pediatric cancer treatment is limited. Furthermore, systematic reviews exploring factors related to
adherence have demonstrated that many of the studies examining potential factors were conducted
roughly two decades ago and few attempted to determine underlying reasons for nonadherence
(Butow et al., 2010; Festa et al., 1992; Gupta & Bhatia, 2017; Lancaster et al., 1997; Lansky et al.,
1983; McGrady & Pai, 2019; Partridge et al., 2002; Ruddy et al., 2009; Tebbi et al., 1986).
Notwithstanding, the current literature elucidates that adherence patterns for pediatric and
adolescent patients with cancer may be related to several distinct factors.
Treatment-Level Factors. Adherence patterns may be associated with treatment-related
factors such as disease or treatment duration, insurance, timing of medication administration, and
medication dosage (which may serve as a proxy measure of pill burden if the patient is required to
take more than one pill in a single administration or medication multiple times a day). Indeed,
lower rates of adherence have been associated with treatment related factors such as: when
medication is taken (e.g., decreased adherence over weekend compared to weekday; Psihogios et
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al., 2021), reliance on Medicaid or the Children’s Health Insurance Program (Wu et al., 2018),
higher 6MP dosage (Bhatia et al., 2015), and treatment duration (e.g., adherence patterns decrease
over time or the longer you have to take a daily oral medication; Bhatia et al., 2012, 2014; Rohan
et al., 2015). Adherence is also known to be associated with non-treatment related factors,
including individual- and family-level factors.
Individual-Level Factors. Adherence can also be related to several individual-level
factors. For example, lower adherence rates have been associated with factors such as lower
motivation/decreased mood (Psihogios et al., 2021). There is substantial evidence that patients
diagnosed with oncology disorders often report increased psychological distress including higher
levels of anxiety and depression, decreased physical activity, increased fatigue, and decreased
quality of life (QoL) across their illness trajectories (Armenian et al., 2013; Kahalley et al., 2013;
Kazak & Noll, 2015; Paltin et al., 2018). In a study investigating the psychological needs of
adolescent and young adult (AYA) cancer survivors, 82% of cancer survivors expressed having at
least one concern related to behavioral, cognitive, and emotional domains across their illness
trajectories, from diagnosis to survivorship (Paltin et al., 2018). There are a number of factors
associated with depressive symptoms that might impact maintenance phase adherence, including
feelings of hopelessness (e.g., feeling that treatments are not worthwhile), social withdrawal
and/or isolation (e.g., absence of necessary emotional support and assistance from others), and
cognitive impairments (e.g., forgetting, errors in self-management; DiMatteo et al., 2000; Drotar
& Rohan, 2014; Wu et al., 2010). While the relationship between patient depression and
adherence have not been explored in the maintenance phase of pediatric cancer treatment, past
work with children with cystic fibrosis demonstrated that increased child depressive symptoms
predicted significantly lower rates of adherence to airway clearance (Smith et al., 2010).
Similarly, past work with adolescents with inflammatory bowel disease found that youth with
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higher anxiety/depressive symptoms reported lower adherence (Gray et al., 2012). As such,
exploring youth-reported depressive symptoms as a possible factor related to adherence during
maintenance treatment is warranted.
Studies focused on caregivers’ psychosocial functioning during cancer treatment have
demonstrated similar increases in anxiety, stress, and depression over the course of treatment
(Katz et al., 2018; Rosenberg et al., 2014). Although the relationship between caregiver
depression and adherence in the maintenance phase has not been explored, past work examining
adherence in children with asthma found that higher maternal depressive symptoms were related
with forgetting to give their child their medication (Bartlett et al., 2004), less confidence in
managing their child’s asthma (Bartlett et al., 2004), and decreased adherence (Bartlett et al.,
2004; Margolis et al., 2021, 2022). Given caregivers’ important involvement in pediatric cancer
treatment, including administering their child’s medication, it is possible that caregiver depressive
symptoms also significantly relate to adherence to 6MP during the maintenance phase.
While patient and caregiver QoL have also been extensively examined over the course of
cancer treatment (Armenian et al., 2013; Bakula et al., 2020; DeWalt et al., 2015; Hullmann et al.,
2010; Kazak & Barakat, 1997; Klassen et al., 2011; Langeveld et al., 2002; McDougall & Tsonis,
2009; Mullins et al., 2016), our understanding of the relationship between QoL and medication
adherence remains limited. Past research examining the relationship between adherence and QoL
within samples of children with chronic conditions (e.g., irritable bowel disease, liver transplant,
sickle cell disease, asthma), demonstrates a potentially bidirectional relationship. For example,
across pediatric chronic conditions, nonadherence may have an impact on QoL as a result of the
need to miss school or social activities because of hospitalizations and medical appointments
(Rapoff, 2010). Specifically, among pediatric liver transplant recipients, adolescents with lower
adherence reported more limitations in social and school activities related to physical, emotional,
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and behavioral problems (Fredericks et al., 2008). Additionally, in a sample of pediatric patients
with Crohn’s, nonadherence to their immunosuppressant medication (e.g., 6MP, 1-2 pills a day),
as measured by biological assay, was related to decreased patient-reported physical health QoL
(Hommel et al., 2009).
Previous work has also demonstrated that adherence can negatively impact QoL. For
example, pediatric patients with Crohn’s who reported greater self-reported adherence to their
inflammation medication (e.g., 5-ASA, 12-18 pills a day) reported lower overall psychological
QoL (Hommel et al., 2009). This is consistent with past work highlighting inverse relationships
between routine burden and QoL among pediatric patients with asthma (Fiese et al., 2005) and
adherence and QoL among pediatric patients with sickle cell disease (Barakat et al., 2005).
Similar relationships may exist between 6MP adherence and QoL among pediatric cancer patients
in the maintenance phase of treatment. For example, nausea is a known side effect of 6MP and
patients receiving cancer treatment have reported greater nausea than patients off treatment on
cancer-specific HRQoL measures (Varni et al., 2002). Thus, it is possible that greater adherence
could result in increased nausea and, consequently, greater nausea may result in nonadherence.
While the relationship between adherence and QoL has not been explored during the maintenance
phase of cancer treatment, it is possible that a bidirectional relationship may also exist among
pediatric patients with cancer.
Further, perceived health beliefs (e.g., lower perception of illness severity) can also affect
adherence rates (Jamison et al., 1986). A systematic review of qualitative studies exploring
caregivers’ views of adherence in chronic pediatric conditions, not including cancer, indicated
that a main factor associated with adherence are beliefs about the condition or treatment (Santer
et al., 2014). Specifically, patients and families reported weighing the perceived effectiveness or
necessity of medication versus the fears of side effects and other concerns (Santer et al., 2014).

20

While past work examining adherence in the maintenance phase of pediatric cancer has not
examined how beliefs about medication relate to adherence, it is possible that these beliefs
influence children’s health behaviors. Indeed, a focus group study exploring adherence barriers
among adolescents in the maintenance phase indicated that favorable blood counts after periods
of intermittent nonadherence (e.g., missing medication for a week) made them view the
medication regimen as less necessary as there were no immediate negative consequences for
their health behaviors (Malbasa et al., 2007). As such, patient’s health beliefs related to the
maintenance phase of treatment, particularly the positive outcomes they expect from adhering or
not adhering to treatment, and the negative effects they fear will occur from following their
treatment regimen, may impact their adherence over time.
It is well documented that there is individual variability in health behaviors across the
illness trajectory, especially within adolescent oncology populations. In fact, lower adherence
over the course of treatment is often related to transitioning into adolescence (Bhatia et al., 2012;
Jamison et al., 1986; Mancini et al., 2012; Partridge et al., 2002; Reed-Knight et al., 2014).
Furthermore, adolescent oncology patients often report increased neurocognitive deficits,
including deficits in executive functioning, memory, concentration, and attention, which may
ultimately lead to worse adherence patterns (Evan & Zeltzer, 2006; Gutiérrez-Colina et al., 2016;
Kazak & Noll, 2015). Adolescent patients with cancer also have unique developmental challenges
compared to their younger peers (Landier, 2011). Both pediatric and adolescent patients report
increased psychological distress, adjustment difficulties, and decreased quality of life; however,
adolescent patients often report additional difficulties specific to this challenging developmental
period, including: a threatened sense of safety and reduced security, feelings of loss of control,
body image concerns, decreased self-esteem and modified sense of self, difficulties with
interpersonal relationships, disruptions in daily life (e.g., academics, employment), increased
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caregiver-adolescent conflict, and a threatened sense of independence (Evan & Zeltzer, 2006; Sisk
et al., 2019; C. E. Wakefield et al., 2010). The developmental difficulties of transitioning from
middle to late adolescence are often amplified for adolescents with chronic illnesses. In fact,
across pediatric chronic illness populations, many emerging adolescents and their parents report
difficulties with balancing parental monitoring and support while avoiding unnecessary reminders
that seem like trivial “nagging” and ultimately result in adolescent rebellion (Mulvaney et al.,
2008; Naimi et al., 2009; Rohan & Winter, 2021; Taddeo et al., 2008). Moreover, parents often
report ongoing difficulties between supporting adolescent autonomy while minimizing risk for
prematurely transferring responsibility for self-management completely to the adolescent
(Peterson-Sweeney et al., 2003; Reed-Knight et al., 2014). Additionally, past work has
demonstrated that children’s perceptions of caregiver involvement evolve across developmental
phases (Taylor et al., 2010). As such, developmental phase during the maintenance phase of
treatment is an important variable to consider as a potential predictor of adherence behaviors.
Particularly among adolescents, patients found to be nonadherent to their cancer treatment
regimen reported higher levels of depression, lower self-esteem, higher levels of caregiver-child
relationship discord (e.g., poor communication, increased conflict), and incongruent reports of
home environment/family functioning patterns between adolescents and their parents (Kennard et
al., 2004). Simultaneously, research demonstrates that adherence rates can be positively impacted
by targeted interventions, such as daily reminders (Psihogios et al., 2021) and playing video
games focused on managing cancer treatment and the common issues associated with managing
such a complex regimen (Kato et al., 2008). As such, identifying and understanding the
individual- and family-level factors related to adherence may better inform future intervention
development geared at addressing these modifiable factors related to adherence.
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Family-Level Factors. When considering family-level factors in children’s adherence, it
is clear that pediatric treatment adherence is impacted by unique challenges due to the critical
importance of family involvement in care (Drotar & Rohan, 2014; Riekert & Drotar, 2000;
Rohan & Winter, 2021). Children depend on their caregivers in numerous ways, as caregivers
are often responsible for acquiring, dispensing, and monitoring medications. Typically, as
children age and demonstrate increased responsibility, autonomy, and independence, treatment
responsibilities become shared between adolescents and their caregivers. Past work has
highlighted that behavioral challenges related to adherence during cancer treatment can evolve as
children age (Landier, 2011). For example, babies may have difficulties swallowing medication,
young children may dislike the taste of oral medication, and adolescents may begin to refuse
medications. As children begin to transition into adolescence, their desire for autonomy may
increase, while their ability to understand long-term consequences are still developing (Landier,
2011).
Prior research has hypothesized that caregiver-child relationship dynamics, including a
lack of communication and increased conflict, between caregivers and adolescents regarding
who is responsible for monitoring or administering medication may be related to lower
adherence rates in adolescence (Tebbi, 1993). Indeed, past work exploring adherence to
medication among adolescents with chronic illnesses, including pediatric cancer, found that
positive family relationships and open communication supported adherence (Jamison et al.,
1986; Kennard et al., 2004; Kyngäs, Kroll, et al., 2000; Rohan & Winter, 2021). Similarly,
families with higher conflict and/or poorer communication styles, had higher rates of
nonadherence (DiMatteo, 2004). Accordingly, considering youth’s family context in the form of
caregiver-child communication and conflict dynamics is critical when examining factors that
may relate to adherence during the maintenance phase of treatment.
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Another important factor to consider when assessing youth’s family context is the
makeup of their home, as it often shapes family daily life. Past research examining treatment
nonadherence in youth with chronic medical conditions that require daily medication (e.g.,
asthma, diabetes, HIV) found that parents often report feeling as though adherence behaviors
need to be considered in the context of balancing the everyday needs of their child with a chronic
illness within the daily needs of the family (Rohan & Winter, 2021; Santer et al., 2014; Verma &
Rohan, 2020). This balancing often involves considering the needs of other children and
members in the home. It has been posited that the individualized needs of siblings can
complicate family routines around medication management in homes where a child has a chronic
illness (Fiese et al., 2005). Furthermore, past reports indicate that caregivers note the stress of
getting their children to school in the morning as a barrier to antiretroviral medication adherence
in young children infected with HIV (K. J. Roberts, 2005). It is possible that the presence of
children or siblings in the home who are younger than the patient, and potentially need more
caregiver attention and support, causes competing demands for caregivers trying to maintain
family routines around medication management (Fiese et al., 2005). While this past work was
not specific to children in treatment for pediatric cancer, it is possible that caregivers may weigh
similar factors when managing daily medications regimens in the maintenance phase. Indeed,
prior work found that the number of siblings in the home was negatively correlated with cancer
treatment adherence (Tebbi et al., 1986). Although factors such as caregiver-child
communication and number of younger siblings/children in the home have not been explored
during maintenance phase of cancer treatment, it is possible that these family-level factors may
impact youths’ adherence.
Significant economic, ethnic, and racial disparities in clinical outcomes for pediatric
patients diagnosed with cancer are well documented (Bhatia, 2011; Bhatia et al., 2012; Buchanan
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et al., 2014; Pritchard et al., 2006). Having a child diagnosed with pediatric cancer could have
negative impacts on the entire family system, including: an impact on parent/caregiver
employment, finances, and sources of emotional and social support (Kazak et al., 2015; Wiener
et al., 2015). Additionally, minoritized children may have an increased risk for medication
toxicities, which may contribute to increased family stress and a higher risk of nonadherence
(Bhatia, 2011; Bhatia et al., 2012). In fact, longitudinal data from a large cohort of children with
leukemia (N = 575) demonstrated those from high poverty areas were more likely to experience
inferior overall survival rates compared to patients from low poverty areas (Bona, 2018).
Furthermore, some past work has indicated varying levels of adherence among minoritized and
non-minoritized youth with cancer (i.e., Latinx, Black, and Asian; Bhatia et al., 2012, 2014),
while other work has found no ethnic group differences (Rohan, Drotar, et al., 2015). Moreover,
while exploring the relationship between demographic factors (e.g., family structure, household
income, parental education) and adherence rates within the COG cohort, Bhatia and colleagues
(2012, 2014) demonstrated that these associations can vary across racial/ethnic groups. For
example, while parental education was significantly related to adherence among Black (maternal
education) and non-Latinx white (paternal education) children, it was not related to adherence
among Asian (Bhatia et al., 2014) or Latinx children (Bhatia et al., 2012). Moreover, while Black
and non-Latinx white children had higher adherence in single-parent/single-child households
than in “nuclear family” households (Bhatia et al., 2014), Latinx children in single-parent
households had lower adherence rates (Bhatia et al., 2012). Lastly, while household income
impacted Asian patients’ adherence, household income was not related to adherence among
Black, Latinx, or non-Latinx white children (Bhatia et al., 2012, 2014). Of note, Bhatia and
colleagues did not consider the intersection between race and ethnicity (Bhatia et al., 2014); thus,
it is unclear if any of the Black or Asian children in their sample were also Latinx. Furthermore,
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while this work indicates that demographic factors may differentially affect adherence in these
diverse groups, these demographic level factors do not shed light on the mechanisms or
underlying causes of these relationships. Nevertheless, these results highlight the importance of
improving our understanding of which factors influence adherence not just among the greater
pediatric cancer population, but within racial and ethnic groups.
The Importance of Including Latinx Pediatric Cancer Patients in Clinical Trials
Simply comparing rates of adherence across racial and ethnic groups is not enough to
understand the nuances of adherence and nonadherence in these unique groups. Despite
guidelines calling for the inclusion of minoritized youth in clinical trials and cancer research
(National Institutes of Health, 2001), the current literature on childhood cancer patients indicates
that those from diverse racial and ethnic backgrounds are seldomly included (Aristizabal et al.,
2015; Burke et al., 2007; Chen et al., 2014; Faulk et al., 2020; Ford et al., 2008; Samuel et al.,
2020; Sateren et al., 2002; Underwood, 2000). Particularly underrepresented are Latinx
childhood cancer patients (Carney et al., 2020; Munet-Vilaró, 2004; Samuel et al., 2020; Walsh
& Ross, 2003). Although systematic reviews have reported on Latinx cancer patients’ outcomes,
this work has largely focused on adulthood breast cancer (Samuel et al., 2020). The lack of
representation of Latinx childhood cancer patients has been attributed to exclusion based on
language requirements, barriers to participation, and issues reporting racial/ethnic categories
(Aristizabal et al., 2015; Giuliano et al., 2000; Gray et al., 2014; Walsh & Ross, 2003; Yancey et
al., 2006).
While total cancer rates for Latinx children are lower than their non-Latinx white
counterparts, incidents of ALL are approximately 20% higher among Latinx children (Miller et
al., 2018). Additionally, Latinx children are known to have lower rates of leukemia survivorship
(Bhatia et al., 2002; Kadan-Lottick et al., 2003; Miller et al., 2018) and may be less likely to
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access survivorship clinic follow-up care (Isaac et al., 2020; Klosky et al., 2008; Milam et al.,
2015). These incongruences have been closely associated with socioeconomic status, insurance
status, and access to quality health care (Bhatia et al., 2002; Miller et al., 2018). Due to
disparities in access to healthcare, Latinx children diagnosed with cancer are often underserved
and understudied (Cain et al., 2020; Jones et al., 2010).
Available data regarding adherence among Latinx children in the maintenance phase of
treatment is limited (Bhatia et al., 2012; Landier et al., 2017; Rohan, Drotar, et al., 2015).
Among the two studies examining adherence rates over time, one study reported lower rates of
adherence among Latinx children when compared to non-Latinx white children (Bhatia et al.,
2012), while the second did not find racial/ethnic differences related to adherence (Rohan,
Drotar, et al., 2015). Of note, Bhatia and colleagues (2012) found that Latinx children in the
COG cohort were at a 2.6-fold increased risk of disease relapse compared to non-Latinx white
children. While past work has posited that the increased rate of relapse among Latinx children
may be due to lower rates of medical adherence and follow-up visit attendance (Pritchard et al.,
2006; Solari, 2014), Bhatia and colleagues (2012) demonstrated that risk of relapse differed by
level of adherence. Specifically, while risk of relapse was comparable between Latinx and nonLatinx white children at adherence levels less than 90%, Latinx patients continued to
demonstrate higher risk of relapse at adherence rates exceeding 90% (Bhatia et al., 2012).
Investigators hypothesized that even in the presence of adequate systemic exposure to 6MP,
underlying genetic factors may influence relapse risk among Latinx children (Bhatia et al.,
2012).
Given that Latinx children who are adherent to their medication regimen continue to be at
an increased risk of relapse, promoting and maintaining adherence among Latinx children is
critical to help reduce modifiable risk factors associated with worse health outcomes. The third
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study that examined adherence during the maintenance phase of treatment and recruited a 37%
Latinx sample focused on a comparison of self-report and electronic monitoring of 6MP intake in
childhood ALL (Landier et al., 2017). Results indicated that Latinx caregivers overreported
adherence rates when compared to non-Latinx white caregivers (Landier et al., 2017). While
reasons for overreporting were not explored, these results indicate that objective measures of
adherence may help to better capture adherence within this population. A better understanding of
adherence among Latinx pediatric cancer patients is needed to inform care and strengthen
intervention relevancy to patients and their families (Bava et al., 2017; Coard et al., 2007;
Munet-Vilaró, 2004). As such, the current study is poised to make a significant contribution to
the literature with regards to understanding health behaviors and outcomes of Latinx children
diagnosed with cancer in the maintenance phase of cancer treatment.
Rationale and Significance of the Current Study
The primary focus of the current study was to identify individual- and family-level
predictors of medication adherence patterns during the maintenance phase of treatment for
pediatric ALL and LBL patients ages 7-19 years (N = 139). Adherence to 6MP medication is
critically important for the survival and long-term success of pediatric ALL and LBL patients.
6MP is an oral medication that is administered daily and can be feasibly and reliably monitored
with measures such as electronic monitors (e.g., MEMS: AARDEX Corporation, Palo Alto, CA)
and pharmacological measures such as biological assays. Prior research with this same cohort of
pediatric patients (N =139) demonstrated that electronic monitoring and pharmacological
measures of 6MP both validly and reliably described treatment adherence patterns over the
course of 15-months within this sample (Rohan et al., 2017). Additionally, this past work
established that results of the electronic monitoring data were directly related to the results of a
pharmacological measure of treatment adherence. Those with low metabolite levels of 6MP
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also had much lower adherence rates based on electronic monitoring and those with metabolite
profiles indicating optimal adherence also had much higher adherence results (Rohan et al.,
2017). Thus, electronic monitoring data is a valid indicator of 6MP adherence patterns over
time in this sample and served as the adherence metric in the current study.
Prospective studies of adherence have generally noted deterioration in treatment
adherence over time (Bhatia et al., 2012; Lau et al., 1998; Pai et al., 2008; Pritchard et al., 2006),
but little is known about patterns and changes in 6MP medication adherence over time.
Additionally, the relationship between individual- and family-level factors that may relate to
adherence during the maintenance phase of treatment for pediatric cancer have largely been
unexplored. Furthermore, this cohort of pediatric patients was intentionally recruited from sites
known to serve Latinx communities to better understand adherence within this population. As
such, this study addressed several limitations of previous research by using objective adherence
data to describe the relationship between medication adherence and individual- and family-level
factors over 15 months, within a sample that is 34% Latinx.
Past work has demonstrated that adherence can be related to individual-level factors such
as health beliefs (Malbasa et al., 2007; Santer et al., 2014), child and parent emotional
functioning (Kennard et al., 2004; Lansky et al., 1983; Psihogios et al., 2021), and family-level
factors such as caregiver-child communication and conflict (Kennard et al., 2004; Kyngäs, Kroll,
et al., 2000; Rohan & Winter, 2021) and number siblings (Tebbi et al., 1986). The current study
expanded our understanding of how these factors might predict adherence patterns in the
maintenance phase of pediatric cancer.
Furthermore, past work exploring the relationship between quality of life and medication
adherence is limited. Likewise, the directionality of the relationship between quality of life and
medication adherence is not well understood (Pai & Drotar, 2010). Past work within pediatric
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populations with chronic illnesses (Barakat et al., 2005; Fiese et al., 2005; Fredericks et al., 2008;
Hommel et al., 2009) indicate a potentially bidirectional relationship. As such, the current study
aims to examine a bidirectional model of adherence predicting quality of life and quality of life
predicting adherence; to better understand the relationship between quality of life and medication
adherence during the maintenance phase of pediatric cancer.
Specific Aims, Research Questions, and Hypotheses
The current study has three proposed aims. See Table 1 for a description of the aims,
hypotheses, and proposed data analyses. Prior research in this cohort of pediatric patients with
ALL and LBL, aged 7-19 years, demonstrated three mutually exclusive patterns of treatment
adherence over time, both across one month (Rohan, Drotar, et al., 2015) and across 15-months
(Rohan & Geaney, 2018) of observation (Figure 1): optimal adherence (e.g., nearly 100%
adherence across time), moderate adherence (e.g., average of 60% adherence over time), and (3)
chronic nonadherence (e.g., approximately 40% adherence over time). The current study aims to
extend past work describing adherence patterns during the maintenance phase of treatment
across the first month (Rohan, Drotar, et al., 2015) and across 15-months (Rohan & Geaney,
2018) of adherence monitoring by further describing and examining individual and family-level
predictors of 6MP adherence trajectories across 15 months.
Aim 1: Aim 1 was to describe the characteristics of patients following different
adherence patterns across 15 months (i.e., optimal adherence, moderate adherence, chronic
nonadherence). We hypothesized that youth in the moderate adherence and chronic
nonadherence groups would be older than youth in the optimal adherence group. We also
hypothesized that 6MP dosage would be variable across the three groups, with youth in the
optimal adherence group having the lowest 6MP dose (i.e., less pill burden), youth in the
moderate adherence group having the second lowest dose, and youth in the chronic
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nonadherence group having the highest dose (i.e., greatest pill burden). This was a variable of
interest given that the number of daily 6MP pills increases as the dosage increases ultimately
leading to increased pill burden.
Due to the small sample sizes of both the chronic nonadherence (n = 17) and moderate
adherence (n = 36) subgroups relative to the optimal adherence subgroup (n =88), the chronic
nonadherence and moderate adherence groups were combined into a single subgroup, referred to
as the “nonadherent group,” for all analyses discussed in Aims 2-3. The optimal adherence group
was referred to as the “adherent group.”
Aim 2a: Aim 2a was to identify predictors of 6MP medication adherence patterns in a
cohort of pediatric cancer patients. We hypothesized that higher levels of caregiver and patient
depression, greater number of younger siblings/children in the home, and higher beliefs of
negative outcomes from taking medication would predict membership in the nonadherent group.
We further hypothesized that more frequent communication, greater intent to adhere to
treatment, and higher beliefs of positive outcomes from taking medication would predict
membership in the adherent group.
Aim 2b (Exploratory Analyses): Aim 2b was an exploratory analysis to examine
whether predictors of 6MP medication adherence differed between ethnic groups (i.e., Latinx,
non-Latinx, white), similar to past work (Bhatia et al., 2012, 2014). Given past work
demonstrated differences in adherence patterns across several demographic, individual, and
family-level factors, we hypothesized that predictors of adherence might differ between Latinx
patients and non-Latinx, white patients. Moreover, given that past research with this cohort
(Rohan, Drotar, et al., 2015) did not find adherence differences across ethnic groups at one
month, we do not have specific directions for these relationships.
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Aim 3 (Exploratory Analyses): Multivariate models were used to examine bidirectional
relationships between quality of life and 6MP adherence in a cohort of pediatric cancer patients
during the maintenance phase of treatment. We hypothesized that behavioral patterns of
nonadherence would predict lower total quality of life and lower rates of nausea. A second model
was examined to determine if total quality of life and nausea-specific quality of life predicted
adherence subgroup membership. It was hypothesized that quality of life (total, nausea-specific)
would predict adherence subgroup membership, such that, those with high rates of total quality
of life would be less likely to belong to the nonadherent subgroup and that those with higher
rates of nausea would likely belong to the adherent subgroup.
Methods
Study Design
This research study was a secondary analysis of data collected as part of two studies,
separately funded by the National Cancer Institute (1R01CA119162 to Drotar; 1F31CA168307
to Rohan). This prospective, multisite randomized controlled trial investigated a family-centered
problem-solving intervention to promote medication adherence among pediatric cancer patients
who were in remission and completing the maintenance phase of treatment. Adherence,
psychosocial, and medical data were collected as part of this 15-month longitudinal RCT. The
current research study focused on identifying individual- and family-level factors that predicted
adherence patterns using electronic monitoring technologies. The proposed study aims, and data
analytic plan are separate from the prior research proposed in the original grant submissions and
the subsequent published papers from that grant. The research strategy, aims, and data proposed
here are unique to this dissertation research.
Per HIPAA guidelines at the respective study sites, families were first contacted by their
medical provider via letter or in-person to gain permission for the study team to approach the
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family about the study. If families did not opt out of being contacted, they were approached by
study coordinators at each site to obtain parental permission and consent and assent from
children and adolescents ages 11 years and older. Verbal assent was obtained from patients 10
years and younger. Of the 171 patients and families approached to participate, 18.7% (n = 32)
refused to participate for the following reasons: being too busy (n = 12), not interested (n = 19),
or having no transportation (n = 1). Past comparisons of patients’ and families who participated
in the study with those who did not participate indicated negligible associations with respect to
patients’ age (d = -0.003) and gender (F = 0.09, p = 0.22; Rohan, Drotar, et al., 2015). However,
there was a moderate association in participation rates by ethnic group: non-Latinx, white
patients’ and families refused participation more often (9.4%) compared to Latinx (3.5%) and
non-Latinx, racially minoritized (5.8%) patients’ and families (V = 0.23; p = 0.01; Rohan et al.,
2017).
Participants
Participants were 139 children and adolescents ages 7-19 years who were diagnosed with
ALL or LBL and their primary caregivers. All patients were expected to complete at least one
cycle (84 days) of maintenance treatment prior to completing baseline measures. Patients and
their caregivers were followed at six medical centers across the United States. Ethnicity
distributions were largely representative of each clinic’s sample. The parent study included two
sites that predominately served the Latinx community and who had multilingual research
coordinators and interventionists (Children’s Hospital Los Angeles, Children's Medical Center
Dallas). As such, within the sample 75 (54.0%) identified as non-Latinx, white; 16 (11.5%)
identified as non-Latinx, racially minoritized; and 48 (34.5%) identified as Latinx.
At baseline, the mean age of the sample was 12.29 years (SD = 3.44, range 7-19 years).
Sixty-eight percent of patients identified as male, while 32% identified as female. This is
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characteristic of this type of diagnosis, which is known to affect more males than females.
Duration of cancer diagnosis at baseline ranged from 0.68 to 2.27 years. Demographic and
medical characteristics of the baseline sample are provided in Table 2a. Study procedures were
approved by each site’s Institutional Review Board.
Eligibility Criteria
To be eligible for study participation, participants were required to be diagnosed with
ALL or LBL in remission, prescribed a daily dosage of 6-mercaptopurine (6MP) oral
medication, and finished with at least one cycle (84 days) of the maintenance phase of therapy
for ALL and LBL. Patients were excluded from recruitment efforts if they were diagnosed with a
comorbid chronic condition requiring burdensome treatments (e.g., cystic fibrosis) or diagnosed
with an intellectual disability or psychiatric condition making it difficult to complete study
procedures. At time of study recruitment, additional eligibility criteria were reviewed with
patients and families. Participants were excluded from study participation (n = 7) if they were:
involved in foster care or did not have a primary caregiver available to participate (n = 2) or had
known plans to relocate to another area requiring transfer of all medical care prior to study
completion (n = 5).
Attrition Rates
Past work examining attrition rates of the current sample (Rohan et al., 2017) indicated
12 participants (8.6%) dropped out of the study due to: disease relapse (n = 9, 75%), completing
maintenance therapy prior to study completion (n = 1, 8.3%), and relocation/transfer of care to a
new hospital (n = 2, 16.7%). Of these families, 8.3% (n = 1) completed baseline measures,
33.3% (n = 4) completed 3 months measures, 25% (n = 3) completed 6 months measures, 25% (n
= 3) completed 9 months measures, and 8.3% (n = 1) completed 12 months measures. Those who
dropped out of the study did not significantly differ from those who remained in the study with
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respect to patients’ cumulative behavioral adherence rates, age, and gender (p > 0.05). However,
Latinx patients (n = 8) dropped out more frequently than non-Latinx, white (n = 3) and nonLatinx, racially minoritized (n = 1) patients (V = 0.22; p = 0.04).
Family-Centered Problem-Solving Intervention
Following the baseline study visit, youth and their primary caregivers were randomized
in equal numbers to one of two groups using a stratified random permuted blocks scheme design:
Family Problem Solving Training Intervention (FPST) (n = 69) or Current Psychosocial Care
(CPC) (n = 70; Ko et al., 2021). The primary aim of the RCT involved testing the efficacy of an
FPST intervention that addressed barriers to treatment adherence, including enhancing
adolescent and family problem-solving strategies, facilitating caregiver-adolescent
communication and collaboration, and using behavioral reinforcement to enhance problemsolving skills. The FPST intervention model was a family-based approach designed to address
specific barriers to medication adherence that were commonly experienced by youth with cancer
and their families. The FPST included five in-person visits and two phone visits that were
designed to enhance the durability of intervention effects. The essential features of the
intervention model involved the promotion of caregiver-adolescent problem-solving and team
work in developing solutions to specific barriers to medication adherence, which were identified
during the intervention sessions; improving youth-caregiver communication around cancer
treatment and promoting development of collaborative strategies to improve medication
adherence; promoting parental support and monitoring of medication adherence; and utilizing
behavioral strategies to reinforce adherence to treatment, including engagement and
enhancement of motivation and problem solving methods (Ko et al., 2021; Nezu et al., 1989).
Measures

35

Linguistic Translation Procedures. Twenty-nine parents and six teens completed
measures in Spanish. Existing, validated Spanish-language measures were utilized when
available. Measures not available in Spanish were translated for the current study. Materials were
translated using a back-translation and forward-translation approach to maintain construct and
conceptual equivalence (Knight et al., 2009; Sireci et al., 2006). Consistent with past studies
involving Latinx pediatric cancer patients and their families (Meeske et al., 2004; Sahler et al.,
2005; Varni et al., 2002), conceptual equivalence (e.g., consistent construct meaning across
languages) was evaluated (MAPI Research Institute, 2019). Principal investigators at the Los
Angeles and Dallas sites worked closely to ensure that translated materials were applicable to the
families at each site. Similar to a prior multisite problem-solving intervention program in
pediatric oncology that used an index dialect (Sahler et al., 2005), the Mexican dialect was
utilized across measures, as the majority of Latinx patients and families in Los Angeles and
Dallas were of Mexican origin. Clarifications for Spanish speakers from other countries were
provided, as needed.
Demographics. Caregivers completed a demographics form at baseline and an updated
form at 15 months. Information was collected about youth (age, gender, grade, race, ethnicity,
birth order, medical history), their caregiver, and family socioeconomic status (caregiver age,
sex, relationship to child, marital status, occupation, educational background, and income). Due
to the numerous developmental milestones that occur between the ages of 7 years and 19 years,
developmentally appropriate age groups were examined. These age groups included: preadolescence (7–9.99 years), early-middle adolescence (10-14.99 years), and middle-late
adolescence (15-19 years). Baseline demographics were utilized in the current study.
Medical Characteristics and Prescribed Medical Treatment. Medical charts were
reviewed at quarterly intervals (baseline, 3, 6, 9, 12, and 15 months) using standardized forms to
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obtain information. Data collected included information on prescribed treatment regimens:
medication type, dose, and timing of administration. It is notable that 6MP is only available in
50mg pills. As such, dosage provides us with a proxy measure for pill count and, consequently,
pill burden. Prescribed medical treatment was standardized across all sites based on treatment
protocols for ALL and LBL implemented by the Children’s Oncology Group (COG), which
facilitated data collection across each site. Information regarding the prescribed treatment
regimen was used to operationalize nonadherence (e.g., discrepancy between the daily dosage of
6MP versus what had been taken by the patient as measured by electronic monitoring). Similar
procedures have been used in previous research studies of adherence (Hommel et al., 2018;
Quittner et al., 2000; Rapoff & Calkins‐Smith, 2020; Rohan et al., 2010, 2013).
Electronic Monitoring of 6MP. An electronic monitoring device (i.e., the Medication
Event Monitoring System (MEMS®) from the AARDEX Corporation, Palo Alto, CA) was used
to monitor daily adherence to 6MP oral medication across 15 months. The MEMS® system is a
prescription bottle that contains a micro-electronic chip in the cap, which registers dates and
times when the bottle is opened and closed. Time-stamped medication events were stored in the
MEMS® device and transferred to a program (i.e., PowerView) that records the daily history of
medication taking. This information can be exported to statistical programs for analysis.
Patients and families were aware of adherence monitoring but were not given feedback
regarding their medication adherence. Patients and families were instructed to take their 6MP
only from the MEMS® bottle for the duration of the study, not to open the bottle unless they are
taking a dose of medication at that time, and to close the bottle immediately after removing the
prescribed dose. A standardized form was used during each download to capture information
regarding extra openings, refills, and periods of nonuse during the previous three-month period.
Adherence was defined as the number of times that oral medication was taken as prescribed
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(Hommel et al., 2018; Lau et al., 1998). Electronic monitoring of oral medication usage has been
used by several investigators to study medication adherence in a range of pediatric chronic
illnesses (Hommel et al., 2018; Rapoff, 2010; Rapoff & Calkins‐Smith, 2020; Wu et al., 2013),
including ALL and LBL (Kondryn et al., 2009; Lau et al., 1998; Rohan et al., 2017; Rohan,
Drotar, et al., 2015). Past work evaluating group based trajectory modeling for the current
sample identified three distinct trajectories of adherence for 131 youth in the sample (Rohan,
Drotar, et al., 2015). As such, the analytic sample for adherence group differences was 131 at
baseline.
During the quarterly MEMS downloads, research assistants collected information from
patients and families about difficulties with using the MEMS cap, including any difficulties that
were experienced when using the MEMS cap as a proxy to an already established medication
administration system such as a pill box. Families who used the MEMS Cap with an already
established medication administration system were asked to open the MEMS cap each time that
medication was removed from the other medication administration system. Electronic monitoring
data for families in either group who indicated difficulties with using the MEMS cap were coded as
a “non-monitored period” (i.e., missing data as this period did not reflect adherence or
nonadherence patterns). Families in either group who indicated that they opened the MEMS device
each time that a pill was ingested or removed from a medication bottle or pill box were included in
all data analyses. Electronic monitoring data for patients and families who had periods of
nonadherence but did not indicate difficulties with using the MEMS cap were included in the
analyses and data was captured as true nonadherence. Patients and families who opted to use a pill
box system to limit existing difficulties they were having with taking medication as prescribed
were permitted to do so. The medical team corroborated reports of nonadherence difficulties.
Given information regarding established patterns of nonadherence for proxy users and the level
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of quality control in place for electronic monitoring data, the electronic monitoring data reflected
here is likely an accurate representation of adherence rates over time. Thus, MEMS user type
was not included as a covariate in data analyses.
Quality of Life. Health-related quality of life (HRQoL) was assessed using the 27-item,
modular instrument, PedsQL 3.0 Cancer Module (Varni et al., 2002). There are three agespecific versions: young child (5-7), child (8-12), and teen (13-18). Caregiver-proxy and
children/teen self-reports were collected via paper-pencil format at baseline, 6 months, and 15
months. At those same timepoints, younger children (7 years) were administered the PedsQL 3.0
Cancer Module via a standardized interview format conducted by research assistants (Appendix
A); the interview scale was consistent with the standard format for administration. The PedsQL
3.0 Cancer Module was specifically designed to measure HRQoL in pediatric cancer
populations. These measures assess total HRQoL and 8 separate domains of HRQoL. In addition
to total HRQoL scores, the Nausea subscale domain was utilized in this study. Items include: ' I
become sick to my stomach when I have medical treatments,’ ‘I feel too sick to my stomach to
eat.’ Responses were recorded on a Likert scale ranging from (0) never a problem to (4) almost
always a problem, for caregiver-proxy and adolescent self-report measures. Young child (7
years) interview responses were anchored from (0) not at all to (2) a lot, using smiley faces
(Appendix B). Scores were transformed to a 0–100 scale, with higher scores indicating more
positive HRQoL. Cronbach’s alpha for whole sample, Latinx sample, and non-Latinx sample, at
baseline, 6 months, and 15 months are presented in Table 3.
Beliefs about Medication. The BAMS is a 59-item scale that asks respondents to rate, on
a 7-point Likert scale, how much they agree or disagree with statements about their illness and
its treatment. The BAMS was administered to youth at baseline, 6 months, and 15 months to
assess beliefs about medication over time. Younger children (<11 years) were administered the
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BAMS through an interview format (Appendix C) with research assistants utilizing visual aids
(i.e., smiley faces) to anchor responses (Appendix D). Adolescents (>11 years) completed the
BAMS independently via paper-pencil format. The endpoint anchors of the scale were (1)
strongly disagree and (7) strongly agree, except for four intent items, which had the anchors of
(1) definitely not likely and (4) definitely likely. The BAMS included four subscales: Perceived
Threat (PT; e.g. ‘I do not think my illness is a serious illness’), Positive Outcome Expectancy
(POE; e.g. ‘If I take my medicine the way the doctors say I should, it helps keep me feeling
well’), Negative Outcome Expectancy (NOE; e.g. ‘The side effects of my medicine are so bad
that I do not want to take it’), and Intent to Adhere (IA; e.g. ‘I want to take every dose of my
medicine the way the doctor says I should’). Lower scores on the NOE and PT subscales reflect
fewer adherence barriers. Higher scores on POE and IA subscales reflect fewer adherence
barriers. Subscale scores were utilized when examining patients’ beliefs about medication.
Cronbach’s alpha for whole sample, Latinx sample, and non-Latinx sample, at baseline, 6
months, and 15 months are presented in Table 3.
Depressive Symptoms of Patients and Caregivers. Depressive symptoms were
assessed with the Children’s Depression Inventory (CDI; patients) and Beck Depression
Inventory (BDI; caregivers) at baseline, 6 months, and 15 months. The CDI is a 27-item, reliable
and valid youth self-report measure (Kovacs, 1992) that has been used to successfully identify
depression in clinical samples of children and adolescents diagnosed with a chronic illness and
referred from medical specialty clinics (Shemesh et al., 2005). Each item offers three sentence
response options, unique to each item, which are scored as 0, 1, or 2. As such, total raw scores
range from 0 to 54, with higher scores reflecting greater levels of depression. CDI raw scores of
>11 are often used as a predetermined cutoff suggesting significant symptoms (Germann et al.,
2014; Shemesh et al., 2005). Standardized T-scores, based on population norms (Kovacs, 1985,
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1992), were used for descriptive analyses, consistent with past work in pediatric cancer
populations (Germann et al., 2014). Cronbach’s alpha for whole sample, Latinx sample, and nonLatinx sample, at baseline, 6 months, and 15 months are presented in Table 3.
The Beck Depression Inventory (BDI), a 21-item self-report rating inventory, was used to
measure caregiver symptoms and attitudes characteristic of depression (Beck et al., 1961).
Respondents are asked to select the statement in each item group that best describes how they
have been feeling in the past week, including today. Each item offers 4 sentence response
options, which are scored 0, 1, 2, or 3. Total scores range from 0 to 63. Scores higher than 20
indicate a clinical level of depression. Cronbach’s alpha for whole sample, Latinx sample, and
non-Latinx sample, at baseline, 6 months, and 15 months are presented in Table 3.
Parent-Adolescent Communication and Conflict. The Parent-Adolescent Conflict
Scale (PAC), a brief version of the Issues Checklist (IC; Robin & Foster, 1989) was completed
by children and caregivers separately at baseline, 6 months, and 15 months. The PAC assessed
general family communication by asking about 15 issues commonly discussed in adolescence
(e.g., which friends they can spend time with, what they can watch on television, chores around
the house). For each issue, the respondent was asked whether the issue was discussed in the past
2 weeks and if so, how many times the issue was discussed and how intense the discussions
were. Frequency of communication was recorded on a 4-point Likert scale from (1) not often to
(4) very often. For this study, a total frequency value was derived by totaling discussion
frequency scores across the 15 items. Possible total discussion frequency values ranged from 0
(no items discussed) to 60 (every item discussed very often). Not discussing an item was coded
as 0. Intensity (or level of conflict) was reported on a 5-point Likert scale from (1) calm to (5)
very angry. Mean intensity was computed by dividing the frequency total by the number of
issues discussed, to assess average conflict across issues. Total discussion frequency Cronbach’s
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alphas for whole sample, Latinx sample, and non-Latinx sample, at baseline, 6 months, and 15
months are presented in Table 3. Cronbach’s alphas could not be calculated for the mean
intensity subscale given the variability in the number of items discussed between individual
respondents.
Quality Control of Data Used in the Proposed Study. All study data was sent to
CCHMC (the Central Coordinating Site) and was cleaned by research coordinators in Cincinnati
under the supervision of J. Rohan. Electronic monitoring data was reviewed for quality and data
integrity and issues were addressed with specific site personnel. Electronic monitoring data was
stored in a secured database and double-checked for accuracy.
Data Analytic Plan
See Table 1, which provides a summary of the analyses that were conducted for Aims 13, including the aims/hypotheses, data analytic methods, and purpose of each analysis.
Aim 1: Describe Characteristics of Medication Adherence Subgroups. As described
in prior research conducted by Rohan and colleagues (Rohan, Drotar, et al., 2015; Rohan &
Geaney, 2018), three adherence trajectories were identified within this cohort at both baseline
and 15-months using Latent Group-based Trajectory Modeling (LGTM) approaches (Jones et al.,
2001; Jones & Nagin, 2007; Nagin, 2005; Rohan et al., 2015): optimal adherence, moderate
adherence, and chronic nonadherence. Behavioral adherence trajectories across 15-months are
described in Figure 1. Table 4 provides LGTM model estimates for each trajectory group. As
shown in Figure 1, the majority of patients (n = 88, 67.1 %) demonstrated exemplary adherence
rates across 15 months: starting at 96.3% (week 1) and decreasing at a rate of -0.10% per week;
such that at 15 months behavioral adherence was 94.8%. A second, smaller, group (n = 26, 20%)
demonstrated poor adherence at the start of monitoring based on electronic monitoring data
(67.6% at week 1), which remained relatively stable over time, decreasing at a rate of -0.01% to
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an average of 67.5% at 15 months. The third and smallest group (n = 17, 12.9%) never
established an adequate pattern of behavioral adherence with adherence levels of only 62.7% at
baseline and decreasing at a rate of -2.8% per week; such that at 15 months adherence was
approximately 30%. To address Aim 1, description of individual- and family-level characteristics
across the three medication adherence subgroups, descriptive statistics were run for demographic
and medical data as well as individual- and family-level factors across the three groups. Here,
means, standard deviations, and ranges for continuous demographic and criterion variables were
calculated. For categorical demographic and criterion variables, percentages were examined (see
Tables 2 and 5).
Preliminary Analyses for Aims 2 and 3: Clinically-relevant demographic and medical
characteristics were compared across the two groups (adherent and nonadherent) using
correlations, independent t-tests (continuous variables), or chi-squares (categorical variables) to
determine which demographic and medical variables, if any, should be included as covariates in
statistical models described in Aims 2-3 (see Table 2b and Table 6). Normality distributions and
homogeneity of variance were examined (as relevant) for all continuous variables included in
this study. Generalized linear models were used for categorical outcomes, which are appropriate
for both normal and non-normal distributions. Based on prior research (Bhatia, 2011; Bhatia et
al., 2012; Davies & Lilleyman, 1995), the following covariates were examined: patient gender,
patient age, patient ethnicity/race, single caregiver versus two caregiver households, diagnosis
duration, and 6MP dose.
Results of the randomized controlled trial indicated that there were no significant
differences in behavioral medication adherence between those patients who participated in the
family-centered problem-solving intervention compared to those who received clinical care as
usual (p = 0.12, d = 0.21; Ko et al., 2021; Rohan, 2014). However, given the potential
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importance of group membership on relevant psychosocial and health outcomes for individual
patients, RCT group was explored as a possible covariate in preliminary analyses for Aims 2-3.
Aim 2a: Identification of Predictors of 6MP Medication Adherence. Aim 2a
examined whether individual- and family-level factors (e.g., baseline number of younger
siblings/children in home and sibling age group, longitudinal health beliefs, child and caregiver
depression, and caregiver-child communication) predicted 6MP adherence group membership.
To account for collinearity and shared variance between caregiver- and child-reported
communication, two separate models were run: one including child-reported communication and
the second including caregiver-reported communication. The primary analysis utilized
longitudinal mixed effects models to examine whether the above individual- and family-level
factors predicted 6MP medication adherence subgroups (adherent vs. nonadherent), as measured
by electronic monitoring. Generalized linear mixed effects models (mixed effects longitudinal
logistic regression) were used to identify predictors of medication adherence group (adherent
versus nonadherent). The GENMOD procedure in SAS 9.4 was utilized as this procedure uses an
iterative fitting process to fit a generalized linear model to the data using maximum likelihood
estimations (Johnston, 1993). This procedure is suitable for outcome variables with both normal
and non-normal distributions. Working correlation structures were examined for all models (e.g.,
unstructured vs structured vs exchange; child vs parent) and the “best fit” models were chosen
using the appropriate model fit statistics (e.g., AIC, QIC, QICu values, which are dependent on
the model type used for the analysis; Cui, 2007; Vaida & Blanchard, 2005). Fit statistics are used
to compare models against one another, with the smallest value indicating the best fitting model
(Cui, 2007; Pan, 2001). Analyses were conducted with SAS 9.4 and SPSS 28. See Table 1,
which provides a summary of the analyses conducted for Aim 2a.
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Aim 2b (Exploratory Analyses): Examine Potential Between Group Differences of
Predictors of 6MP Medication Adherence. Aim 2b examined whether the individual- and
family-level factors (number of younger siblings/children in home, health beliefs, and child and
caregiver depression) that predicted 6MP adherence patterns (adherent vs. nonadherent) varied
across Latinx and non-Latinx, white children (Table 2b). The primary analysis utilized
generalized longitudinal binomial logistic regression to examine whether the above individualand family-level factors that predicted 6MP medication adherence subgroup, as measured by
electronic monitoring, differed across ethnic groups (Latinx vs. non-Latinx, white children).
Given the exploratory nature of these analyses and the lack of directional hypotheses, Bonferroni
corrections were evaluated for these analyses. Analyses were conducted with SPSS 28. See
Table 1, which provides a summary of the analyses conducted for Aim 2b.
A Priori Power Analysis. Using past work that investigated the relationship between
individual- and family-level factors and medication adherence/health outcomes in pediatric
cancer and pediatric type 1 diabetes (Rohan et al., 2017; Rohan, Drotar, et al., 2014, 2015;
Rohan, Huang, et al., 2014; Rohan, Rausch, et al., 2015), a total sample size of 109 patients was
needed for the univariate and multivariate analyses to yield at least 90% power for the analyses
proposed in Aims 2a and 2b.
Aim 3 (Exploratory Analyses): Examine the Bidirectional Relationship Between
Adherence and Quality of Life. Aim 3 included exploratory analyses examining the
bidirectional relationship between 6MP adherence subgroups and quality of life. The analyses
utilized both general linear mixed models for normal/continuous outcomes (mixed ANOVA)
and generalized linear mixed effects models for non-normal/categorical outcomes (mixed
effects longitudinal logistic regression) to examine bi-directional relationships between 6MP
medication adherence and quality of life (total quality of life score, nausea quality of life score).
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To account for collinearity between child- and caregiver-reported quality of life responses, a
separate child-reported model and caregiver-reported model was evaluated.
A Priori Power Analysis. Using prior research from the current parent study
investigating the relationship between medication adherence and quality of life (Bolden & Isaac,
2020), a sample size of 109 patients was needed to yield at least 90% power for the proposed
Aim 3 analyses that examined the bi-directional relationship between 6MP adherence and QoL.
Results
A description of the data analytic methods utilized to examine Aims 1-3, and their
associated hypotheses, are presented in Table 1.
Aim 1: Description of characteristics for each of the three adherence group trajectories
across 15-months in a cohort of pediatric cancer patients
Demographic and Medical Characteristics. Descriptive statistics for the study’s
baseline variables are presented in Table 2a. Characteristics were evaluated for the full sample
(N = 139) and those in the three adherence trajectory groups (n = 131). We hypothesized that
youth in the moderate adherence and chronic nonadherence groups would be older than youth in
the optimal adherence group. This hypothesis was partially supported. While youth in the
optimal adherence group were found to be significantly younger than those in the moderate
adherence group (Mdiff = 1.83 years, p = 0.04) at baseline, youth in the chronically nonadherent
group were not significantly older than youth in the optimal adherence group (Mdiff = 1.60 years,
p = 0.179) at baseline. There were no significant differences across the groups with respect to
baseline: patient gender, education, ethnicity, number of kids in the home, caregiver gender,
caregiver marital status, income, household composition (one versus two caregiver home), or
whether there were older kids present in the home (p > 0.05). However, results did indicate that
youth in the chronically nonadherent group were more likely to have younger kids present in the
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home at baseline compared to youth in the optimal and moderate adherence groups, χ2 (1, 130) =
9.82, p = 0.007.
With respect to medical characteristics, the majority of patients in this sample were
diagnosed with ALL (96%). Four percent of patients were diagnosed with LBL. Time since
diagnosis at baseline did not significantly differ across the three adherence groups (p = 0.64).
We hypothesized that 6MP dosage (i.e., a proxy to pill burden) would vary across the three
adherence groups, with youth in the optimal adherence group having the lowest 6MP dose
(which equates to taking less total oral pills in a single administration (i.e., less pill burden as
6MP pills only come in 50mg increments), youth in the moderate adherence group having the
second lowest dose, and youth in the chronic nonadherence group having the highest dose
(which equates to taking the most total daily 6MP 50mg pills in a single administration (i.e., high
pill burden)). This hypothesis was partially supported (see Table 5). Specifically, youth in the
optimal adherence group were prescribed significantly lower doses of 6MP than those youth in
the moderate adherence group at baseline (~1.5 pills vs. >2 pills), 6 months (~1.5 pills vs. >2
pills), and 15 months (~2 pills vs. >2.5 pills; p < 0.05). However, youth in the chronically
nonadherent group did not have significantly higher doses of 6MP compared to youth in the
moderately adherent group (Mdiff = 7.56 mg, p > 0.05). In fact, youth in the chronically
nonadherent group were prescribed significantly lower 6MP doses at baseline compared to youth
in the moderate adherence group at baseline (Mdiff = 28.94 mg, p < 0.05). Dosage did not
significantly differ between the moderate adherence group and chronically nonadherent group at
6- or 15-months (p > 0.05). Additionally, dosage did not significantly differ for youth in the
optimal adherence or chronically nonadherent groups at baseline, 6-, or 15-months (p > 0.05).
Individual and Family Level Factors. Group comparisons of additional individual- and
family-level factors were exploratory (Table 5). Evaluation of child-reported depressive
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symptoms revealed that very few youth (n = 4) in the present study reported T-scores indicating
clinically significant levels of depressive symptoms at baseline (n = 2), 6 months (n = 2), or 15
months (n = 2). At each time point, only 1.4% of youth reported clinically significant levels of
depression. The mean CDI total raw scores ranged from 0.9 to 2.0 (out of a possible 54) across
groups and time points. Neither raw CDI nor CDI T-scores differed across the groups (p > 0.05).
Conversely, approximately 10% of caregivers reported clinically significant levels of depressive
symptoms on the BDI at baseline, 6 months, and 15 months. However, neither mean BDI score
nor percentage of caregivers reporting clinically significant levels of depressive symptoms
significantly differed across the three adherence groups (p > 0.05).
Child- and caregiver-reported communication and conflict were also compared across the
three groups. Child-reported total communication frequency did not significantly differ between
the three adherence groups at baseline or 6 months (p > 0.05). However, at 15-months, youth in
the chronically nonadherent group reported having significantly less discussions with their
caregivers (M = 6.1, SD = 4.8) than youth in the optimal adherence group (Mdiff = 7.7, F(2, 113)
= 4.1, p = 0.017). Average child-reported conflict also did not significantly differ across
subgroups at baseline, 6 months, or 15 months (p > 0.05). Finally, results did not indicate
significant differences in caregiver-reported total communication frequency or average conflict
at baseline, 6 months, or 15 months (p > 0.05).
Youth-reported beliefs about medication were also evaluated across groups and time
points. Youth in the optimal adherence group reported higher positive outcome expectancy (e.g.,
‘If I take my medicine the way the doctors say I should, it helps keep me feeling well’) at
baseline compared to youth in the moderate adherence group (Mdiff = 8.0, p = 0.031). Positive
outcome expectancy ratings did not vary between the optimal adherence group and the
chronically nonadherent group nor the chronically nonadherent group and moderately adherent
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group (p > 0.05). Further, there were no significant differences across groups with respect to:
perceived threat, negative outcome expectancy, or intention, at baseline, 6 months, or 15 months
(p > 0.05).
Preliminary Analyses Aims 2a and 2b
Normality and homogeneity of variance criteria were met as relevant. Due to the small
sample sizes of both the chronic nonadherence (n = 17) and moderate adherence (n = 36)
subgroups relative to the optimal adherence subgroup (n = 88), the chronic nonadherence group
and the moderate adherence group were combined into a single subgroup, referred to as the
“nonadherent group,” for all analyses discussed in Aims 2-3. The optimal adherence group was
referred to as the “adherent group.” Based on prior research (Bhatia, 2011; Bhatia et al., 2012;
Davies & Lilleyman, 1995; Rohan et al., 2017; Rohan, Drotar, et al., 2015; Rohan & Winter,
2021), the following covariates were examined for inclusion in analyses, baseline: patient age
group (pre-adolescence: 7-9.99 years, early-middle adolescence: 10-14.99 years, middle-late
adolescence: 15-19 years), patient gender, patient ethnicity and race, single caregiver versus two
caregiver households, maternal education, household income, and diagnosis duration (Table 2a
and Table 6). Results indicated that age group (Figure 2) and 6MP dosage (at baseline, 6 months,
and 15 months, Figure 3) were significantly related with adherence group membership in the full
sample. All other demographic and medical characteristics were not significantly related to
adherence group membership in the full sample. As such, baseline age group and longitudinal
6MP dosage were added as covariates into predictive models for Aim 2a.
Results of the randomized controlled trial indicated that there were no significant
differences in behavioral medication adherence between patients who participated in the familycentered problem-solving intervention compared to those who received clinical care as usual (p =
0.12, d = 0.21; Rohan et al., 2017). Nevertheless, given the potential influence of group
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membership on individual- and family-level factors, group membership was examined as a
potential covariate in preliminary general linear models. These preliminary analyses did not
indicate that RCT group membership was significantly related to adherence trajectory group
membership (Table 6). As such, RCT group membership was not included as a covariate in
predictive models for Aims 2a or 2b.
Alternative competing models were examined for Aim 2a to determine which specific
predictor variables should be included in the final comprehensive predictive model. Predictor
variables that were significantly related to adherence group membership in preliminary analyses;
or, had a theoretical rationale based on prior research, were included in the final predictive
models. It is notable that child-reported depressive symptoms, caregiver-reported depressive
symptoms, and child- and caregiver-reported conflict scores were not included in final predictive
models given the limited range and variability of scores for these measures and the lack of
statistical significance found in preliminary analyses. Finally, all competing models were
examined based on best fit statistics for each model and the models with the best statistical fit
were chosen as the final predictive model. Baseline patient age group and number of younger
children in the household, and longitudinal dosage, beliefs about medication (POE, Intent, NOE),
and caregiver-child communication were retained as predictor variables in Aim 2a analyses.
Aim 2a. Identifying predictors of 6MP medication adherence group (adherent versus
nonadherent) in a cohort of pediatric cancer patients
Generalized linear mixed effects models (mixed effects longitudinal logistic regression)
were used to examine predictors of medication adherence group membership (adherent versus
nonadherent). Given preliminary analyses indicating that child-reported depressive symptoms,
caregiver-reported depressive symptoms, and child-/caregiver-reported conflict were not
significantly related to medication adherence group membership in univariate analyses,
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hypotheses regarding the relationship between these predictor variables and medication
adherence group membership are considered unsupported. Thus, Aim 2a analyses focused on
whether developmental phase, number of younger children in the home, beliefs that negative or
positive outcomes would occur from taking medication, adherence intent, 6MP dosage, or
caregiver- or child-reported communication patterns predicted risk for nonadherence (Table 2b).
To account for collinearity and shared variance between caregiver- and child-reported
communication patterns, two separate models for child- and caregiver-report were separately
examined (Table 7): one including only child-reported communication and the second including
only caregiver-reported communication, which is similar to other predictive models investigating
health outcomes in pediatric chronic illness (Rohan, Huang, et al., 2014).
Child-Reported Communication Model. As hypothesized, when controlling for all
other factors, developmental phase was significantly related to increased risk of nonadherence (p
= 0.007; see Tables 2b and 7). Pre-adolescents were 0.25 times less likely (β = -1.38) to be in the
nonadherent group than youth in the middle-late adolescent age group. Similarly, early-middle
adolescents were 1.44 times less likely (β = -0.37) to be in the nonadherent subgroup compared
to middle-late adolescents. Additionally, as hypothesized, when controlling for all other factors,
as 6MP dosage increased the risk of being nonadherent also increased (OR: 1.0, p = 0.02, see
Figure 3). In contrast, when controlling for all other factors, the number of younger kids in the
home (p = 0.50, see Table 7), NOE (p = 0.18, see Figure 4), POE (p = 0.08, see Figure 5), Intent
(p = 0.07, see Figure 6), nor child-reported total communication frequency (p = 0.29, see Figure
7) significantly predicted nonadherence risk. The child-reported communication mode had a
model fit statistic (QICu) of 435.67.
Caregiver-Reported Communication Model. Consistent with the child-reported
communication model, as hypothesized, when controlling for all other factors in the caregiver-
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reported model, developmental phase also was significantly related to increased risk of
nonadherence (p = 0.008; see Tables 2b and 7). Pre-adolescents were 0.24 times less likely (β = 1.44) than middle-late adolescents to be nonadherent. Those in early-middle adolescence were
1.61 times less likely (β = -0.48) to be in the nonadherent group than those in middle-late
adolescence. Additionally, as hypothesized, when controlling for all other factors, as 6MP
dosage increased the risk of being nonadherent also increased (OR = 1.0, p = 0.04, see Figure 3).
In contrast to the child model, when controlling for all other factors, youth who reported higher
outcome expectancies were less likely to be nonadherent (OR: 1.0, p = 0.02, see Figure 5).
Indicating that youth who expected fewer positive outcomes from taking their medication were
at an increased risk of being nonadherent. Moreover, similar to the child-reported model, when
controlling for all other factors, number of younger kids in the home (p = 0.34), NOE (p = 0.16),
Adherence Intent (p = 0.19), and caregiver-reported total communication frequency (p = 0.12,
see Figure 8) did not significantly predict increased risk of nonadherence. With caregiverreported communication entered in the model, model fit (QICu) was 379.2, indicating that
caregiver-reported communication was a better predictor than child-reported communication
based on model fit statistics (Hardin & Hilbe, 2012).
In order to further understand the relationship between age group and the remaining
independent variables, exploratory one-way ANOVA analyses and an additional linear
regression were conducted. Results of these exploratory analyses indicated significant
differences between age groups across several domains (Table 8). Particularly notable was the
significant positive relationship between age group and 6MP daily dosage. Specifically, a oneunit increase in age group at baseline was associated with a 70.7mg increase in 6MP dosage at
baseline (F(1, 137) = 20.32, R2 = 0.13, p < 0.001), a 74.6mg increase in dosage at 6 months (F(1,
131) = 27.57, R2 = 0.17, p < 0.001), and a 90mg increase in dosage at 15 months (F(1, 108) =
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32.01, R2 = 0.22, p < 0.001). Indicating that older adolescents were prescribed significantly
higher doses of 6MP than younger youth.
Aim 2b. Exploratory Analyses: Examine between group differences of predictors of 6MP
medication adherence (adherent vs nonadherent) in a cohort of pediatric cancer patients
Aim 2b explored potential between group differences of predictors of 6MP medication
adherence group membership. As such, analyses focused on two subsamples: (1) Latinx patients
(n = 47) and (2) non-Latinx, white patients (n = 76). In order to determine which predictors to
include in predictive analyses, descriptive statistics were run for demographic and medical data
as well as individual- and family-level factors across the two adherence groups (adherent vs
nonadherent; Table 2b). For these analyses, means, standard deviations, and ranges for
continuous demographic and criterion variables were calculated. For categorical demographic
and criterion variables, percentages were examined. A total of two cross sectional and seven
longitudinal t-tests were run within each subsample. As such, Bonferroni corrections indicated a
necessary p value of 0.006 at each timepoint to reject the null hypothesis (R. A. Armstrong,
2014).
Latinx Patients. Comparisons of demographic factors indicated no significant differences
between the Latinx youth in the nonadherent and adherent groups with respect to baseline:
patient gender, age, maternal education, number of people in the home, caregiver gender,
caregiver marital status, income, household composition (one versus two caregiver home), or
whether there were younger or older children present in the home (p > 0.05). With respect to
medical characteristics, time since diagnosis at baseline did not significantly differ across the
adherence groups (p = 0.55; Table 2b). Conversely, 6MP dose differed between the two groups
at baseline and 15 months. Specifically, Latinx youth in the adherent group were prescribed
lower doses of 6MP than Latinx youth in the nonadherent group at baseline (Mdiff = 33.5, t(43) =
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2.28, p = 0.03, Bonferroni p > 0.006) and 15 months (Mdiff = 45.9, t(32) = 2.63, p = 0.01,
Bonferroni p > 0.006); however, these differences did not remain significant when examining the
Bonferroni corrected p value. Dosage did not significantly differ between the two groups at 6
months (p = 0.14).
Analyses examining individual- and family-level factors revealed no significant
differences between the adherence groups’ mean caregiver-reported depression, child-reported
total communication, caregiver-reported total communication, and several domains of health
beliefs (i.e., negative outcome expectancy, perceived threat, intention). Results did, however,
indicate that Latinx youth in the adherent group reported higher positive outcome expectancy at
baseline (e.g., ‘If I take my medicine the way the doctors say I should, it helps keep me feeling
well’) than youth in the nonadherent group (Mdiff = 9.0, t(43) = -2.35, p = 0.02, Bonferroni p >
0.006); however, these differences did not remain significant when examining the Bonferroni
corrected p value. Child-reported positive outcome expectancy did not significantly differ at 6or 15-months (p > 0.05).
Given these preliminary analyses, only 6MP dose and positive outcome expectancy were
retained as possible predictors of adherence among Latinx youth in Aim 2b analyses. To
conserve power in our predictive analyses, 6MP dose and positive outcome expectancy were
examined in two separate longitudinal binomial logistic regressions.
6MP Dose. A longitudinal logistic regression analysis assessed whether 6MP dose across
time significantly predicted adherence group membership among Latinx youth. A test of the full
model against the constant only model was significant, χ2 (3) = 7.91, N = 47, p = 0.048,
Nagelkerke R2 = 0.30, indicating that 6MP dose significantly differed over time between those
who were in the adherent group versus those in the nonadherent group. Specifically, Latinx
youth with higher 6MP doses were at increased risk for nonadherence. According to Wald
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criterions, however, cross-sectional dose at baseline, 6 month, and 15 months did not
individually predict adherence group membership (p > 0.05). These results indicate that
investigating longitudinal patterns of 6MP dosage over time is a better predictor of adherence
group membership among Latinx youth compared to investigating only a single point of time.
Positive Outcome Expectancy. A longitudinal logistic regression analysis assessed
whether child-reported positive outcome expectancy across time significantly predicted
adherence group membership among Latinx youth. A test of the full model against the constant
only model was not significant, χ2 (3) = 5.69, N = 47, p = 0.13, Nagelkerke R2 = 0.20. However,
according to Wald criterions, positive outcome expectancy at baseline significantly predicted
adherence group membership (p = 0.04). Specifically, the change in odds associated with oneunit change in reported positive outcome expectancy (at baseline) was 0.086, indicating that
higher reported positive outcome expectancy at baseline increased likelihood of adherent group
membership. Thus, in this model, baseline positive outcome expectancy was a better predictor of
adherence group membership among Latinx youth than positive outcome expectancy over time.
Non-Latinx, white Participants. Comparisons of demographic factors (Table 2b)
indicated that non-Latinx, white (hereafter referred to as white) youth in the nonadherent group
were more likely to be older than those in the adherent group, χ2 (2, 71) = 6.86, p = 0.03, at
baseline. There were more youth in middle-late adolescence in the nonadherent group (42%)
compared to the adherent group (19%). Youth in the adherent group were more likely to be in
pre-adolescence (51%) compared to older peers who were more likely to be in the nonadherent
group (21%). Comparisons of additional demographic factors indicated no significant differences
between the white youth in the nonadherent and adherent groups with respect to baseline: patient
gender, maternal education, number of people in the home, caregiver gender, caregiver marital
status, income, household composition (one versus two caregiver home), or whether there were

55

younger or older children present in the home (p > 0.05). With respect to medical characteristics,
time since diagnosis did not significantly differ across the two adherence groups (p = 0.51).
Conversely, 6MP dose significantly differed between the groups at baseline and 15 months.
Specifically, white youth in the adherent group were prescribed lower doses of 6MP than white
youth in the nonadherent group at baseline (Mdiff = 21.2, t(69) = 2.62, p = 0.01, Bonferroni p >
0.006) and 15 months (Mdiff = 23.2, t(56) = 2.06, p = 0.04, Bonferroni p > 0.006); however, these
differences did not remain significant when examining the Bonferroni corrected p value. Dosage
did not significantly differ between the two groups at 6 months (p = 0.32).
Analyses examining individual- and family-level factors revealed no significant
differences between the groups’ mean caregiver reported depression nor health beliefs domains
of negative outcome expectancy, perceived threat, intention, or positive outcome expectancy.
Conversely, results indicated that white youth in the adherent group reported higher
communication frequency at 15 months than youth in the nonadherent group (Mdiff = 5.6, t(59.1)
= -2.6, p = 0.01; Bonferroni p > 0.006); however, this difference did not remain significant when
examining the Bonferroni corrected p value. Moreover, white caregivers whose children were in
the adherent group reported more frequent communication at 6 months (Mdiff = 5.8, t(60.1) =
-2.4, p = 0.019; Bonferroni p > 0.006) and 15 months (Mdiff = 8.0, t(48.7) = -3.3, p = 0.002;
Bonferroni p < 0.006); however, these differences only remained significant at 15 months when
examining the Bonferroni corrected p value. Additionally, caregivers in the nonadherent group
reported significantly greater caregiver-child conflict at baseline than parents in the adherent
group (Mdiff = 0.35, t(62) = 2.9, p = 0.005; Bonferroni p < 0.006). Youth in the adherent and
nonadherent groups did not report significantly different levels of caregiver-child conflict.
Given these preliminary analyses, baseline age group and longitudinal child-reported
total communication frequency, caregiver-reported total communication frequency, and 6MP
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dose were retained as possible predictors of adherence among white youth in Aim 2b analyses.
As in Aim 2a analyses, caregiver-reported communication conflict was not included in predictive
models, as this measure’s Cronbach’s alpha could not be assessed due to small sample size. In
order to conserve power in our predictive analyses, separate binomial logistic regressions were
run for each predictor.
Age Group. A logistic regression analysis assessed whether age group (at baseline)
significantly affected whether white children were in the nonadherent or adherent group. A test
of the full model against the constant only model was significant, χ2(1) = 6.82, N = 76, p = 0.009,
Nagelkerke R2 = 0.13. According to Wald criteria, age group at baseline significantly predicted
whether white youth were in the adherent versus nonadherent group. Specifically, youth in the
pre-adolescence and early-middle adolescence age groups were less likely to be in the
nonadherent group than youth in the middle-late adolescence age group. With a one-unit increase
in age group, the odds of being in the adherent group decreased by –0.83 (p = 0.012). Indicating
that white youth in the middle-late adolescent age group were most likely to be in the
nonadherent group. Thus, being in an older age group at baseline decreased the likelihood of
adherent group membership among white youth.
6MP Dose. A longitudinal logistic regression analysis assessed whether 6MP dose across
time significantly predicted adherence group membership among white youth. A test of the full
model against the constant only model was significant, χ2(3) = 8.71, N = 76, p = 0.03,
Nagelkerke R2 = 0.20, indicating that longitudinal dose significantly predicted adherence group
membership. Moreover, according to Wald criterions, baseline dosage significantly predicted
adherence group membership (p = 0.04). Specifically, the change in odds associated with oneunit change of dose (at baseline) was -0.21, indicating that a higher 6MP dose at baseline
decreased likelihood of adherent group membership. Thus, in this model, both cross-sectional
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baseline dose and dosage over time significantly predicted adherence group membership among
white youth. These findings indicated that 6MP dosage prescribed at baseline accounted for more
of the variance in longitudinal adherence behaviors than dosage at 6 month or 15 month.
Child-Reported Communication Frequency. A longitudinal logistic regression analysis
assessed whether child-reported total communication frequency across time significantly
predicted adherence group membership among white youth. A test of the full model against the
constant only model was significant, χ2(3) = 8.28, N = 76, p = 0.04, Nagelkerke R2 = 0.17.
Higher levels of child-reported communication frequency was associated with decreased risk of
nonadherence. However, Wald criteria indicated that none of the cross-sectional child-reported
total communication scores significantly predicted adherence group membership (p > 0.05).
Thus, longitudinal child-reported communication was significantly better at predicting adherence
group membership in this model than cross-sectional child-reported communication frequency at
baseline, 6 months, or 15 months. Indicating that the pattern of child-reported communication
over time was more predictive of adherence behavior than communication at any isolated
timepoint.
Caregiver-Reported Communication Frequency. A longitudinal logistic regression
analysis assessed whether caregiver-reported total communication frequency across time
significantly predicted adherence group membership among white youth. Similar to the childreported model, a test of the full model against the constant only model was significant, χ2 (3) =
9.77, N = 76, p = 0.02, Nagelkerke R2 = 0.23. Higher levels of caregiver-reported communication
frequency was also associated with decreased risk of nonadherence. However, Wald criteria
indicated that none of the cross-sectional caregiver-reported total communication scores
significantly predicted adherence group membership (p > 0.05). Thus, longitudinal caregiverreported communication was significantly better at predicting adherence group membership in
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this model than cross-sectional caregiver-reported communication frequency at baseline, 6
months, or 15 months. Similarly indicating that the pattern of caregiver-reported communication
over time was more predictive of youth’s adherence behaviors than communication frequency
considered at any isolated timepoint.
Overview of Differences in Predictors Between Ethnic Groups. Exploratory analyses
revealed possible between group differences with respect to predictors of medication adherence
group membership (Table 2b). Among Latinx patients, in single factor models, longitudinal 6MP
dosage and baseline positive outcome expectancy significantly predicted adherence group
membership. Conversely, among white patients, single factor models indicated that baseline age
group, baseline and longitudinal 6MP dose, and longitudinal child-reported and caregiverreported communication frequency significantly predicted adherence group membership.
Aim 3. Exploratory Analyses: Examine bidirectional predictive model of quality of life and
medication adherence
Aim 3 examined the bidirectional relationship between quality of life and 6MP adherence
groups. Due to low Cronbach’s alpha statistics (Table 3) for the PedsQL young child (5-7) form
in this sample, youth under the age of 8 were excluded from Aim 3 analyses. Model fit was
examined with and without youth under the age of 8. Both QIC (fit of overall model) and QICu
(fit of model covariates) improved when excluding youth under the age of 8 (Mdiff = 35 and 36,
respectively). As such, the analytic sample for Aim 3 consisted of 123 youth (aged 8 to 19).
Analyses included general linear mixed models when assessing factors related to HRQoL
and generalized linear mixed effects models when evaluating factors that predict medication
adherence group membership. To account for multicollinearity among child-reported and
caregiver-reported HRQoL, separate child and caregiver models were evaluated. Additionally,
separate total HRQoL and nausea HRQoL models were also evaluated to account for
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multicollinearity among total HRQoL and nausea subscale values. Thus, four separate models
were conducted for each outcome variable: (1) Child-reported total HRQoL, (2) Child-reported
nausea HRQoL, (3) Caregiver-reported total HRQoL, and (4) Caregiver-reported nausea
HRQoL.
Adherence Group Membership as Dependent Variable. Based on Aim 2a results,
baseline age group and longitudinal 6MP dose and POE were included as covariates in the
following predictive models. Based on past work (Tebbi et al., 1986) and theory (Fiese et al.,
2005), number of younger kids in the home was also included as a covariate in the total HRQoL
models.
Child-Reported Total HRQoL as Predictor. When controlling for the above-mentioned
covariates, child reported total HRQoL did not significantly predict adherence group
membership (p = 0.57). Similar to Aim 2a analyses, when controlling for all other factors,
developmental phase was significantly related to increased risk of nonadherence (p = 0.02; see
Table 9). Pre-adolescents were 0.28 times less likely (β = -1.28) to be in the nonadherent group
than youth in the middle-late adolescent age group. Similarly, early-middle adolescents were
0.70 times less likely (β = -0.36) to be in the nonadherent subgroup compared to middle-late
adolescents. Additionally, when controlling for all other factors, as 6MP dosage increased the
risk of being nonadherent also increased (OR: 1.0, p = 0.04, see Figure 3). Moreover, when
controlling for all other factors, as POE increased, the risk of being nonadherent decreased (OR:
1, p = 0.04, see Figure 5). In contrast, when controlling for all other factors, number of younger
kids in the home (p = 0.42, see Table 7) did not significantly predict nonadherence risk. With
child-reported total HRQoL entered in the model, the covariate model fit (QICu) was 396.6.
Caregiver-Reported Total HRQoL as Predictor. When controlling for the abovementioned covariates, caregiver reported total HRQoL did not significantly predict adherence
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group membership (p = 0.59). Similar to Aim 2a analyses, when controlling for all other factors,
developmental phase was significantly related to increased risk of nonadherence (p = 0.02; see
Table 9). Pre-adolescents were 0.28 times less likely (β = -1.28) to be in the nonadherent group
than youth in the middle-late adolescent age group. Similarly, early-middle adolescents were
0.70 times less likely (β = -0.36) to be in the nonadherent subgroup compared to middle-late
adolescents. Additionally, when controlling for all other factors, as 6MP dosage increased the
risk of being nonadherent also increased (OR: 1.0, p = 0.04, see Figure 3). Moreover, when
controlling for all other factors, as POE increased, the risk of being nonadherent decreased (OR:
1, p = 0.03, see Figure X). In contrast, when controlling for all other factors, number of younger
kids in the home (p = 0.42, see Table 7) did not significantly predict nonadherence risk. With
caregiver-reported total HRQoL entered in the model, the covariate fit (QICu) was 394.2.
Indicating that child- and caregiver-reported total HRQoL similarly were equally strong
predictive models.
Child-Reported Nausea HRQoL as Predictor. When controlling for age group,
positive outcome expectancy, and 6MP dose, child-reported nausea HRQoL did not significantly
relate to adherence group membership (p = 0.58). Similar to previous analyses, when controlling
for all other factors, developmental phase was significantly related to increased risk of
nonadherence (p = 0.01; see Table 9). Pre-adolescents were 0.26 times less likely (β = -1.36) to
be in the nonadherent group than youth in the middle-late adolescent age group. Similarly, earlymiddle adolescents were 0.63 times less likely (β = -0.46) to be in the nonadherent subgroup
compared to middle-late adolescents. Additionally, when controlling for all other factors, as 6MP
dosage increased the risk of being nonadherent also increased (OR: 1.0, p = 0.04, see Figure 3).
Contrary to previous HRQoL models, when controlling for all other factors, POE did not
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significantly predict risk of nonadherence (p = 0.053). With child-reported nausea HRQoL
entered in the model, the covariate model fit (QICu) was 400.9.
Caregiver-Reported Nausea HRQoL as Predictor. When controlling for age group,
positive outcome expectancy, and 6MP dose, caregiver-reported nausea HRQoL did not
significantly relate to adherence group membership (p = 0.29). Similar to previous analyses,
when controlling for all other factors, developmental phase was significantly related to increased
risk of nonadherence (p = 0.01; see Table 9). Pre-adolescents were 0.26 times less likely (β = 1.36) to be in the nonadherent group than youth in the middle-late adolescent age group.
Similarly, early-middle adolescents were 0.63 (β = -0.46) to be in the nonadherent subgroup
compared to middle-late adolescents. Additionally, when controlling for all other factors, as 6MP
dosage increased the risk of being nonadherent also increased (OR: 1.0, p = 0.04, see Figure 3).
Contrary to the child-reported nausea model, when controlling for all other factors, as POE
increased, the risk of being nonadherent decreased (OR: 1.0, p = 0.04, see Figure X). With
caregiver-reported nausea HRQoL entered in the model, the covariate model fit (QICu) was
398.5. Indicating that both child- and caregiver-reported nausea HRQoL were equally strong
predictive models.
It was hypothesized that those with lower quality of life scores would have lower
adherence rates and that higher nausea would predict lower adherence. Neither the child- nor
caregiver-reported models supported these hypotheses.
HRQoL (Total and Nausea) as Dependent Variables. All continuous variables were
normal, and homogeneity of variance criteria were met as relevant. Preliminary analyses
examining potential covariates of total HRQoL and nausea HRQoL revealed that the
combination of demographic variables correlated to each DV differed based on respondent (child
versus caregiver). As such, covariates in each of the models were specific to the outcome
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variable (Table 10). Two mixed ANOVAs were conducted to examine whether there were
differences across adherence groups in longitudinal total HRQoL (child- and caregiver-reported).
Two additional mixed ANOVAs were conducted to examine whether there were differences
across adherence groups in longitudinal nausea HRQoL (child- and caregiver-reported).
Relationship Between Adherence Group and Child-Reported Total HRQoL. Within
the child-reported model, only time point was significantly related to total HRQoL (F(2, 84) =
4.53, p = 0.01). Indicating that while child-reported total HRQoL for each adherence group
changed significantly over time, child-reported total HRQoL did not significantly differ between
the two adherence groups (Figure 10). Moreover, although child-reported total HRQoL was
significantly correlated to baseline maternal education, number of people in the home, income,
and ethnicity and race, cross-sectionally, they were not significantly related to longitudinal total
HRQoL (p > 0.05).
Relationship Between Adherence Group and Caregiver-Reported Total HRQoL.
Within the caregiver-reported model, baseline gender, age group, income, and maternal
education were not significantly related to longitudinal HRQoL, despite significant crosssectional correlations (p < 0.05). Significant differences in caregiver-reported total HRQoL were
not observed between the two adherence groups (Figure 11). It was hypothesized that
nonadherence would predict lower total quality of life; neither child- nor caregiver-model
supported this hypothesis.
Relationship Between Adherence Group and Child-Reported Nausea HRQoL.
Within the child-reported model, only timepoint was significantly related to nausea HRQoL
(F(1, 95) = 3.28, p = 0.04). Indicating that while child-reported nausea HRQoL for each
adherence group also changed significantly over time, child-reported nausea did not significantly
differ between the two adherence groups (Figure 12). Although cross-sectionally related to
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child-reported nausea HRQoL, baseline maternal education, study group, and race were not
significantly related to longitudinal total HRQoL (p > 0.05).
Relationship Between Adherence Group and Caregiver-Reported Nausea HRQoL.
Within the caregiver-reported model, baseline gender, age group, income, or maternal education
were not significantly related to longitudinal nausea HRQoL, despite being cross-sectionally
correlated (p > 0.05). Caregiver-reported nausea did not significantly differ between the two
adherence groups (Figure 13). It was hypothesized that higher adherence would predict more
nausea; neither child- nor caregiver-model supported this hypothesis.
Discussion
Adherence during the maintenance phase of pediatric cancer treatment is critical to
prevent relapse and ensure long-term, event-free survival. Comprehensive research investigating
longitudinal predictors of nonadherence in pediatric cancer populations is limited. Although a
number of factors have been proposed as potential barriers to adherence (Bhatia, 2011; Bhatia et
al., 2012; Kondryn et al., 2011; Pritchard et al., 2006; Rohan et al., 2017; Rohan, Drotar, et al.,
2015), including demographic and person-level factors (e.g., patient gender, age, ethnicity, race,
youth and caregiver depressive symptoms, health beliefs and outcome expectations) and
treatment factors (e.g., dose, daily adherence behaviors), these factors are not routinely
investigated in research focused on patterns of medication adherence. As such, the current study
aimed to expand our understanding of factors related to maintenance phase adherence by
examining how additional individual and family level factors, often associated with adherence,
relate to 6MP adherence during maintenance phase. These factors included, but were not limited
to, number of younger children in home, pill burden, developmental phases, health beliefs,
family communication patterns, and health-related quality of life.
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The current study’s aims were threefold: (1) describe individual, family, and medical
characteristics among three medication adherence group trajectories across 15-months, (2)
identify predictors of 6MP medication adherence group membership (adherent vs nonadherent),
and explore potential between group differences (i.e., Latinx, non-Latinx, white) of predictors of
adherence, and (3) examine an exploratory bidirectional predictive model to examine the
relationship between quality of life and medication adherence group membership. Better
understanding of adherence behaviors over time and factors that predict adherence during
maintenance phase are critical for the development of effective and relevant person-centered
resources and interventions.
Characteristics of the three adherence group trajectories across 15-months in a cohort of
pediatric cancer patients
Results demonstrated significant differences in individual-, medical- and family-level
factors across the three adherence groups (Table 2a; Table 5). As hypothesized, youth in the
optimal adherence group were significantly younger (continuous age) than those in the moderate
adherence group and had significantly lower daily 6MP doses than youth in the moderate
adherence group across all three timepoints. Additional findings demonstrated that youth in the
optimal adherence group reported higher positive outcome expectancy from taking their
medication than youth in the moderate adherence group at baseline. These findings indicate that
membership in the optimal adherence group was related to both individual and medical factors.
Moreover, these results support past work indicating that youth’s adherence behaviors are
influenced by their perceptions of the effectiveness and/or necessity of their medications (Santer
et al., 2014) and age (Landier, 2011).
Contrary to our hypotheses, youth in the moderate adherence group were not significantly
older than youth in the chronically nonadherent group and, surprisingly, at baseline youth in the
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chronically nonadherent group were prescribed lower 6MP daily doses (i.e., less pill burden) on
average compared to youth in the moderately adherent group. Although dosage was lower for
those in the chronically nonadherent group compared to those in the moderate adherence group,
these differences did not reach significance. Given the relatively small and uneven distribution of
youth in the moderately adherent versus chronic nonadherent groups, it is possible that these
differences might reach significance in a larger sample. Exploratory analyses indicated that
youth in the chronically nonadherent group reported less frequent general communication with
their caregivers at baseline compared to youth in the optimal adherence group and were more
likely to have younger children in the home compared to youth in the moderate adherence group.
As such, it is possible that membership in the chronically nonadherent group was related more to
family-level factors than individual or medical factors than membership in the other two groups.
These findings lend support to the need to consider social determinants of health and youth’s
home environment when assessing and appraising health behaviors and outcomes (WHO 2016;
CP Jones, 2000; Rohan & Winter 2021).
When collapsing the moderately adherent and chronically nonadherent groups into the
‘nonadherent group’ for analyses in Aims 2-3, age remained significantly different between the
nonadherent and adherent groups, dosage differences were significant at all three timepoints,
baseline positive outcome expectancy remained significantly different between the groups, and
baseline differences in adherence intent across the groups emerged (Table 2b). While general
differences between the adherent and nonadherent groups remained in the expected direction,
future studies may aim to recruit larger samples so that predictive models may not need to be
collapsed. This would allow further exploration into specific factors that predict membership in
three (optimal vs moderately adherent vs chronically nonadherent) with variable intercepts and
slopes, particularly the chronically nonadherent group whose slope (-2.8) was much larger than
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the other two groups (Rohan, Drotar, et al., 2015). That said, it is notable that those in the
moderately adherent and chronic nonadherent groups both never reached adherence levels of
95%, which is indicative of better prognostic factors in pediatric ALL and LBL, including
decreased risk for disease relapse and mortality (Bhatia et al., 2012, 2015).
Identifying predictors of 6MP medication adherence group (adherent versus nonadherent)
in a cohort of pediatric cancer patients
In comprehensive predictive models, examining several factors often related to mediation
adherence, our findings indicated that developmental age group was the strongest predictor of
6MP adherence group (adherent versus nonadherent), even when controlling for other medical(e.g., dose), individual- (e.g., beliefs about medication) and family-level (e.g., number of
younger siblings in home, caregiver-child communication) factors; within both child-reported
and caregiver-reported predictive models. Specifically, youth in the pre-adolescent and earlymiddle adolescent age groups were at significantly lower risk of being in the nonadherent group
than youth in the middle-late adolescent age group. These findings align with past work
indicating that adherence declines over adolescence (Bhatia et al., 2012; Jamison et al., 1986;
Mancini et al., 2012; Partridge et al., 2002; Reed-Knight et al., 2014; Shaw et al., 2003) and that
older adolescents often have unique barriers to adherence that are amplified by their unique and
often challenging developmental period (Evan & Zeltzer, 2006; Gutiérrez-Colina et al., 2016;
Landier, 2011).
Future work exploring adherence in this age group could be strengthened by examining
other domains known to impact health behaviors in older adolescents, such as executive
functioning (Evan & Zeltzer, 2006; Gutiérrez-Colina et al., 2016; Kazak & Noll, 2015), alliance
with health care providers (Steinberg et al., 2020; Trevino et al., 2013), and perceived readiness
for independent self-care (Goethals et al., 2020; Haarbauer-Krupa et al., 2019). Indeed, past
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work examining adolescents’ general attitudes towards and experience with treatment (Barbara
L. Jones et al., 2010; Steinberg et al., 2020), highlights that AYA oncology patients often feel as
though clinic environments are tailored more towards younger patients than older adolescents
and that conversations with medical providers may be difficult to follow (e.g., use of medical
jargon). Guidelines and recommendations to consider when working with AYA populations are
available (Hayes-Lattin et al., 2010; Nass et al., 2015) and may serve as reference guides for
additional domains to consider in future research. Moreover, the current study did not measure
the quality and clarity of conversations with healthcare providers. As such, future work may
benefit from standardized measures of domains of communication between adolescents and
providers (e.g., treatment knowledge, perception of provider openness for questions), as it cannot
be assumed that all patients begin maintenance phase with the same level of treatment
understanding.
While dosage was significantly related to adherence group membership, dosage was not a
stronger predictor than age group in the current model when controlling for all other factors.
Exploratory findings further investigating the relationship between age group and dosage
indicated that age group and dosage were significantly related, such that as age group increased
dosage increased as well. These findings demonstrate that, in general, older adolescents have a
higher pill burden than pre-adolescents and younger adolescents. This is likely related to older
adolescents having a greater BMI due to height and weight, and thus a higher dose intensity
required for continued remission. Currently, 6MP is only available in 50 mg doses, which
increases risk for pill burden especially for adolescents who are already at a vulnerable
developmental period and at risk of nonadherence due to competing demands. Efforts to
advocate for 6MP to be available in various forms (50mg, 75mg, 100mg), at the pharmaceutical
and insurance levels, may be considered as this could help to ameliorate the pill burden older
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adolescents face. Additionally, age group analyses indicated that youth in the middle-late
adolescence group reported significantly higher expectations of negative outcomes from taking
their medication at baseline than youth in the early-middle adolescence group. These findings
suggest that education related to medication should be tailored across the developmental
trajectory, especially as children transition to adolescence, and adolescents to young adulthood,
to meet the patients’ unique developmental needs and concerns. For example, research indicates
that fertility issues often arise as an important topic for older adolescent cancer patients (Evan &
Zeltzer, 2006; Sisk et al., 2019). As such, developmentally appropriate information regarding
how 6MP affects fertility could be important to share with older adolescents, as this may be a
salient potential negative outcome among this age group.
The complex treatment regimen and increased treatment burden for pediatric cancer
patients often poses significant challenges for children, adolescents, and their families. Past work
has demonstrated that increased treatment burden has been related to increased rates of
nonadherence (Pritchard et al., 2006; Ruddy et al., 2009). Previous research also suggests that a
patient’s health beliefs (i.e., how they view their illness and associated treatment) likely directly
influences their medication adherence (Buchanan et al., 2014; Pritchard et al., 2006). Prior
research has proposed that patients who perceive their illness as serious, perceive themselves as
vulnerable, and recognize that treatment will be effective in curing their illness are likely to have
higher rates of medication adherence (Jamison et al., 1986; Malbasa et al., 2007; Santer et al.,
2014). Similar to this past work, our results indicated that higher positive outcome expectancies
increased the likelihood of membership in the adherent group (in the caregiver model).
Interestingly adherence intent nor negative outcome expectancy were significantly predictive of
adherence in the current study. These findings indicate the need and value of education related to
the positive benefits of taking 6MP medication as prescribed. Indeed, focus groups with
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caregivers of children with cancer revealed that even caregivers often wish for more information
regarding treatment timeline, overviews, and possible side effects (Ringnér et al., 2011).
Prioritizing informational sessions related to treatment and the benefits and risks of medication
might help to positively enhance youth’s health beliefs.
Contrary to hypotheses, child- and caregiver-reported depression did not significantly
relate to adherence group membership. Given the restricted range and variability of both
caregiver- and child-reported depressions scores across time in the current cohort it is possible
that the CDI and BDI were not clinically sensitive enough to evaluate the unique psychological
experiences of the youth and caregivers in the current sample. It is also possible that youth and
their caregivers who were included in the present sample had minimal psychological distress and
thus lower rates of depressive symptoms comparative to previous work. Although past work,
including youth with cancer, demonstrated that the CDI can be used in chronically ill populations
with good overall reliability (Saoji et al., 2019), reliability statistics for the CDI in this sample
were low. Due to possible health-related activity restrictions during the maintenance phase of
treatment, semi-structured interviews or open-ended depression measures could be useful in
pediatric cancer populations to differentiate between what youth can and cannot do due to their
treatment/diagnosis and what youth are experiencing due to mood or emotion concerns.
Contrary to hypotheses, caregiver- and child-reported total communication frequency did
not significantly relate to adherence group membership when controlling for other variables of
interest. The Parent-Adolescent Conflict Scale (PAC) questionnaire used in the current study
measured general communication frequency and intensity of conversations related to 15 specific
issues generally discussed during adolescence. While this general communication assessment
provides information regarding how often caregivers and children discuss general topics (e.g.,
chores, homework, hanging out with friends) and how intense these conversations typically
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were, it is possible that simply discussing topics may not be as impactful on health behaviors,
such as adherence, as other caregiver-child dynamics. Guided by systems theory
(Bronfenbrenner, 1979; I. M. Miller et al., 2000) and past work in other pediatric chronic illness
populations (Fredericks et al., 2007; Killian et al., 2018), caregiver-child cohesion and family
functioning are two constructs that should be explored in future work as they might shed light on
important family processes that may be related to medication adherence. It is possible that the
quality of conversations and how understood both parties feel may be more important than the
mere occurrence of conversations. Incorporating measures such as the Family Assessment
Device (Epstein et al., 1983) and the Family Adaptability and Cohesion Scales (FACES III,
Olson, 1986), which is available in Spanish (Flores & Sprenkle, 1989) and has been normed for
Latinx families (Baer & Schmitz, 2007), could strengthen future work. Among Latinx families,
family cohesion is known to be related to acculturation (Baer & Schmitz, 2007). As such,
acculturation and/or biculturalism should also be assessed when examining the relationship
between family cohesion and adherence behaviors among Latinx patients.
Contrary to hypotheses, number of younger children in the home was not significantly
related to adherence group membership. While various family-level factors were evaluated in
this study (e.g., number of younger children/siblings in the home, caregiver- and child- reported
communication frequency and intensity), these measures do not fully capture dynamic family
processes, particularly within the context of pediatric chronic illness management. For example,
although number of siblings in the home has been significantly related to adherence in past work
(Tebbi et al., 1986), conceptually number of younger children/siblings in the home was
considered a proxy measure for competing demands in the household due to other children in the
home. However, a static number of younger children in the home does not directly capture
caregiver demands or shed light on other factors that may cause differences across families with
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the same number of children in their homes. For example, number of siblings does not account
for variable sibling needs (e.g., developmental delays, family expectations, chronic health
conditions) or caregiver-perceived difficulties related to medication adherence in the context of
their unique home and family (e.g., balancing the needs of all children in the home, difficulties
establishing medication routine). The Parent Medication Barriers Scale (Simons & Blount, 2007)
has been used in past work investigating barriers to medication adherence among patients with
inflammatory bowel disease (Reed-Knight et al., 2013) and solid organ transplantation
(Danziger-Isakov et al., 2016); however, this measure assesses perceived barriers related to
adolescents taking their medication (e.g., too many pills, does not like the taste, does not want
friends to see), not perceived barriers for caregiver involvement in medication management or
assessment of a family routine around medication management. As such, future work is
encouraged to assess caregiver/family-specific and caregiver-perceived barriers to involvement
or family-specific reasons for noninvolvement in medication management to better understand
caregiver involvement and how it relates to maintenance phase medication management.
In the predictive models included in Aim 2a, caregiver- and child-reported variables were
evaluated in separate models to account for shared variance and multicollinearity. In the majority
of predictive models, the QICu value did not differ substantially when using child versus
caregiver report, with the exception of total communication frequency. Future work might
benefit from analyzing report congruency and discrepancy (De Los Reyes et al., 2019), as
differences in caregiver- and child-reported accounts (across domains) can provide information
surrounding the caregiver-child relationship. Given past work demonstrating that caregiver-child
discrepancies on parental monitoring assessment was able to predict child delinquent behaviors 2
years later in ways that individual reports could not (De Los Reyes et al., 2010), examining
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discrepancies in reports of caregiver monitoring or involvement in medication management
could shed light on important dynamics that affect adherence.
Identify possible between group differences of predictors of 6MP medication adherence
patterns
Preliminary exploratory analyses indicated possible between group differences (i.e.,
Latinx, non-Latinx white) of predictors of 6MP adherence patterns. Bonferroni corrections
indicated that some cross-sectional relationships did not remain significant based on the
corrected value of p = 0.006. Given that corrections are utilized when analyses do not have
directional hypotheses, specific research questions, or when less robust statistical analyses are
utilized (R. A. Armstrong, 2014), it is recommended that future work prioritize recruiting large
and diverse samples to allow for more robust analyses or identifying possible ethnicity-specific
predictor to allow for apriori hypotheses.
Within the Latinx subsample, single factor models indicated that longitudinal 6MP
dosage and baseline positive outcome expectancy significantly predicted adherence group
membership. Specifically, among Latinx youth as dose increased so did risk for nonadherence
and, conversely, as POE increased risk for nonadherence decreased. Conversely, within the white
subsample, single factor models indicated that baseline age group, baseline and longitudinal 6MP
dose, and longitudinal child-reported and caregiver-reported communication frequency
significantly predicted adherence group membership. Specifically, as age group and 6MP dose
increased risk of nonadherence increased and, conversely, more frequent communication (childand caregiver- reported) was associated with decreased risk of nonadherence. These findings
should be interpreted with caution as single factor models are limited as they do not account for
possible confounding factors. Nevertheless, these findings revealed interesting information about
cross-sectional versus longitudinal analyses and highlight the importance of assessing both cross-
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sectional data and patterns of data when possible. Moreover, these findings highlight the
potential importance of health beliefs in Latinx patients’ health behaviors (Leininger, 1997).
Additionally, the relationship between ethnicity and adherence should be interpreted
cautiously as these analyses centralize outcomes without consideration of processes and social
stratification (García et al., 1996). Latinx pediatric cancer patients’ experiences with cancer
treatment and health behaviors may be significantly influenced by cultural factors, such as
acculturation and values (Gray et al., 2014; Munet-Vilaró, 2004). A main cultural factor that has
been explored to date is acculturation. Acculturation is defined as a process by which contact
with a different culture results in the modification of the culture of a group or individual
(Redfield et al., 1936). Acculturation orientations have been conceptualized in two domains: the
adoption of mainstream culture and/or the maintenance of one’s own ethnic-origin culture, with
various possible combinations that may be related to differing degrees of acculturative stress
(i.e., assimilation, integration; Berry, 2005). Literature supports a bidirectional model of
acculturation and has demonstrated its advantages over focusing on unidimensional models to
predict outcomes, given that individuals can hold multiple cultural orientations (Nguyen &
Benet-Martínez, 2007). As such, recent literature has shifted towards assessing the dynamic
process of cultural adaptation referred to as biculturalism (i.e., the degree to which individuals
have internalized aspects of mainstream and ethnic culture) rather than linear measures of
acculturation. Recent findings indicate that acculturative family distancing is associated with
decreases in family cohesion among US-Born youth and their parents (Nair, Roche, & White,
2018). Thus, including measures of biculturalism, acculturative family distancing, and values in
future work with Latinx patients could provide more information about the nuanced ways that
the dynamic processes of culture relate to health behaviors and outcomes.
Examining a bidirectional predictive relationship between quality of life and adherence
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Given past research demonstrating a potentially bidirectional relationship between
adherence and HRQoL within samples of children with chronic illnesses (Fredericks et al., 2008;
Hommel et al., 2009; Rapoff, 2010), exploratory analyses examined a potential bidirectional
predictive relationship between quality of life and adherence. In this cohort of pediatric oncology
patients, surprisingly, results indicated that longitudinal quality of life (total and nausea) and
adherence trajectories were not significantly related in either direction (e.g., quality of life
predicting adherence, adherence predicting quality of life). Past work focused on populations
with significantly greater pill burden (e.g., Crohn’s 12-18 pills a day; Hommel et al., 2009) and
lifetime chronic illness (e.g., sickle cell, asthma; (Barakat et al., 2005; Fiese et al., 2005). As
such, it is possible that although disease self-management is taxing on patients and families,
adherence and quality of life may not affect each other as much during the maintenance phase of
cancer treatment as in other chronically ill populations. This may be related to having decreased
illness burden during maintenance relative to other phases. In maintenance, patients can often
return to some of the activities they did prior to cancer treatment and have fewer medical visits.
Furthermore, it is important to note that the PedsQL 3.0 Cancer Module had low
Cronbach alpha statistics among Latinx patients who completed the 5-7 year old interview
version (Table 3). Given the low alpha statistics, all youth who completed the 5-7 year old
version were excluded from statistical analyses in Aim 3. These low alpha values align with
findings from past work utilizing the generic PedsQL among an Argentinian sample (α range =
0.28–0.76; Roizen et al., 2008). As such, it is possible that this measure may not be a good fit for
Latinx children and their families. It is possible that construct equivalence may not have
translated sufficiently in this version. For example, the item “Does your medicine make you sick
to your stomach?” was translated directly to “Te hacen sentirte mal del estómago tus
medicinas?” rather than “Tus medicinas te dan un dolor de estómago?/Does your medicine make
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your stomach hurt?” which may have been more culturally and developmentally appropriate for
youth in that age group. Future work should consider other measures of HRQoL for younger (57) Latinx children and their families.
Limitations and Future Directions
While the current study provides important information regarding specific individual,
family, and medical factors that may relate to and predict 6MP adherence during the
maintenance phase of treatment, it is important to note limitations of the current study.
The demographic characteristics of the patients enrolled at each site reflected the general
population in the areas where each hospital was located. Consequently, the generalizability of
current findings is limited to Latinx (predominantly Mexican) and non-Latinx, white patients
receiving maintenance treatment in the geographic regions included in our study. Future multisite studies, should be intentional about including hospitals known to serve Black, Asian, and
Indigenous communities, as these populations are often excluded from pediatric cancer research
(Aristizabal et al., 2015; Chen et al., 2014; Sateren et al., 2002; Underwood, 2000).
Additionally, the generalizability of findings related to Latinx patients’ adherence
behaviors are limited, first, due to study location. Los Angeles and Dallas have strong and
historically established Latinx communities and many institutional supports and resources for
Latinx families (Cobb et al., 2020; Potochnick et al., 2012). Emerging Latinx communities have
distinct needs and barriers (Brietzke & Perreira, 2017; Huq et al., 2016), such as a lack of
bilingual resources (Corona et al., 2009; Wells et al., 2008) and increased concerns of
discrimination (Potochnick et al., 2012). Furthermore, in more established communities, later
generation immigrants with greater English proficiency and insights into navigating barriers may
serve as supports (Duong et al., 2016). Consequently, Latinx patients in emerging Latinx
communities may have markedly different experiences, outcomes, and needs than those in
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established Latinx communities. As such, there is a need for future studies to examine adherence
and factors related to adherence among youth from emerging Latinx communities. Second,
recruitment of Latinx patients and families from other regions and countries of origin would also
help to expand our understanding of adherence across a variety of Latinx communities. Third,
although relatively large compared to past work, the size of the Latinx sample in the current
study (n = 47, 34%) limited the statistical approaches appropriate for our data. Due to power
restrictions, analyses evaluating predictors of 6MP adherence membership among Latinx patients
were limited to one predictor at a time. Thus, it was not possible to assess potential covariates in
our between group (i.e., Latinx; non-Latinx, white) data analyses. Future work should aim to
include a greater number of Latinx patients. This would allow for more powerful statistical
analyses and the ability to examine intersectional identities known to influence family
expectations among Latinx families (e.g., gender socialization; Raffaelli & Ontai, 2004).
Another important limitation relates to the lack of variables measuring child, caregiver,
and family experiences with racism (individual, institutional/structural). This is particularly
notable given the various ethnic and racial groups included in our sample (12% non-Latinx
racially minoritized (e.g., Black, Asian), 34% Latinx). For decades, researchers have elucidated
that racism operates at multiple levels, ranging from internalized to institutionalized (C. P. Jones,
2000; Ture & Hamilton, 1992). The American Academy of Pediatrics has recognized racism as a
core social determinant of health that drives many of the inequities experienced by children and
adolescents (Trent et al., 2019). The World Health Organization (2016) defines social
determinants of health as “the conditions in which people are born, grow, live, work and age.”
These determinants are influenced by factors such as the distribution of money, power, and
resources at global, national, and local levels and have been linked to inequities. Moreover, these
inequities are caused by economic, political, and social conditions (including racism) and not
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individual choices or genetic predisposition (World Health Organization, 2016). Indeed,
institutional racism is known to manifest itself in both ‘material conditions’ (e.g., access to
quality education, neighborhoods, medical facilities) and ‘power’ (e.g., access to information,
resources, and voice; C. P. Jones, 2000), which are often outside of an individuals’ control.
While there is no standard measure for structural racism, past work has relied on various
indices (e.g., redlining, mortgage lending), socioeconomic status data (e.g., employment rate
proportions), and self-report measures (e.g., perceived racism) to investigate the relationship
between structural racism and outcomes (Groos et al., 2018). Studies utilizing these measures
have demonstrated that structural racism impacts a range of health behaviors and outcomes in
adults, including colorectal cancer survivorship (Kacanek et al., 2019), hypertension treatment
adherence (Greer et al., 2014), and delayed HIV testing (Scott et al 2014). Although past work
has demonstrated the relationship between structural racism and child mental health and school
outcomes (S. C. T. Jones & Neblett Jr., 2019; Mougianis et al., 2020; Owens, 2020), research
investigating the relationship between racism and child physical health outcomes and behaviors
is scarce (Pachter & Coll, 2009) and available measures are limited (e.g., forms of racism
assessed, only one racial/ethnic group; Braddock et al., 2021). Nevertheless, measures such as
the Perception of Racism in Children and Youth measure (PRaCY; Pachter, Szalacha, et al.,
2010) have demonstrated promise among pediatric patients with sickle cell disease (E. O.
Wakefield et al., 2018). Future work could benefit from assessing children’s experiences with
racism (individual and institutional) as a means to better understand processes and mechanisms
of inequities (García et al., 1996); particularly with measures designed using qualitative, mixed,
and community-based methodologies (S. C. T. Jones & Neblett, 2017). Recent work by Isaac
and colleagues (2020) provides guidance on several additional biopsychosocial factors and social
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determinants of health that warrant inclusion in future pediatric cancer treatment adherence
studies.
Conclusion
The current study substantially adds to the literature base as it expands our understanding of
factors related to youth’s adherence to 6MP medication during maintenance phase treatment of
ALL and LBL. Findings indicate that adolescent developmental phase was the strongest
predictor of 15-month adherence group membership. Better understanding of potential individual
and family level factors that might impact this relationship is critical so that we may develop
resources and interventions for these youth who are at increased risk for nonadherence, and
consequently relapse. Dosage and health beliefs, specifically positive outcome expectancy, also
significantly predicted adherence group membership. These findings demonstrate the continued
need to provide person-centered tailored interventions to patients, while considering individual
level characteristics. Exploratory analyses indicated the possibility of between group (i.e.,
Latinx; non-Latinx white) differences with respect to predictors of 6MP adherence. Additional
multi-site studies are needed to further explore possible between group differences of predictors
of adherence, as well as examine possible ethnicity-specific predictors of adherence such as
cultural values (e.g., familismo, respeto), spiritualism, biculturalism. This future work may
incorporate measures of cultural values, expectations, and processes to better understand the
underlying drivers for these possible unique predictors. While the current study adds
considerably to our understanding of adherence during maintenance phase, additional work in
this area focused on preventive and therapeutic interventions remains critical to increase positive
outcomes for a vulnerable cohort of patients; and, to ultimately reduce morbidity and mortality
related to medication nonadherence.
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Table 1. Summary of Data Analyses, Research Aims, Hypotheses, and Purpose of Data Analyses for Aims 1-3.
Aims

1. Describe characteristics for each of the
three adherence group trajectories across
15-months in a cohort of pediatric cancer
patients

Hypotheses
• Children in the moderate adherence group will
be older than children in the optimal adherence
and chronic nonadherence groups.
• Dosage will range across the groups, with
children in optimal adherence group (lowest
dose), moderate adherence group (second
lowest dose), and chronic nonadherence
(highest dose)

Data Analytic Method

Purpose of Analysis

• Descriptive Statistics

• Describe individual- and familylevel factors across 15-months for
each of the three group-based
trajectories

Preliminary Analyses for Aims 2-3

• N/A

• Correlations (continuous factors)
• Chi-Square (categorical factors)

• Identify covariates to include in
Aims 2-3 analyses

2a. Identify predictors of 6MP medication
adherence group (adherent versus
nonadherent) in a cohort of pediatric
cancer patients

• Higher levels of caregiver and patient
depression, greater number of younger
siblings/children in the home, greater levels of
caregiver-child conflict, and higher beliefs of
negative outcomes from taking medication will
predict membership in the nonadherent group.
• More frequent communication, greater
adherence intent, and higher beliefs of positive
outcomes from taking medication will predict
membership in the adherent group.

• Generalized linear mixed effects
models (mixed effects longitudinal
logistic regression)

• Identify which individual- and
family-level factors predict
adherence group membership

2b. Exploratory Analyses: Identify
possible between group differences of
predictors of 6MP medication adherence
patterns

• Predictors of adherence might differ between
non-Latinx patients and Latinx patients.

• Descriptive statistics
• Correlations and chi-squares
• Binominal logistic regression

• Determine whether the individualand family-level factors that
predict adherence vary between
Latinx and non-Latinx white
children

3. Exploratory Analysis: Examine
bidirectional predictive relationship
between quality of life and adherence

• Nonadherence will predict lower total quality of
life scores
• Those with lower quality of life scores will have
lower adherence rates
• Higher nausea will predict lower adherence

• General linear mixed models for
normal/continuous outcomes
• Generalized linear mixed effects
models for non-normal/categorical
outcomes (mixed effects
longitudinal logistic regression)

• Examine bidirectional model of
adherence group predicting
quality of life and quality of life
predicting adherence group

Abbreviations. N/A, not applicable; 6MP, 6-mercaptopurine
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Table 2a. Demographic and Medical Characteristics of Baseline Sample and Trajectory Groups (3 group)
Full Sample
(N = 139)
12.29 (+3.4)

Optimal
Adherence
Group (n =88)
11.75 (3.38)a

Moderate
Adherence
Group (n = 26)
13.57 (3.36)

Chronically
Non-adherent
Group (n = 17)
13.34 (3.4)

Mean Patient Age, M (SD)
Patient Age Group, n (%)
Pre-adolescence (7-9.99)
50 (36)
38 (43)
5 (19)
3 (18)
Early-Middle adolescence (10-14.99)
48 (35)
30 (34)
10 (39)
7 (41)
Middle-Late adolescence (15-19)
41 (29)
20 (23)
11 (42)
7 (41)
Type of Cancer Diagnosis, n (%)
ALL
133 (96)
16 (13)
25 (20)
85 (67)
LBL
6 (4)
1 (20)
1 (20)
3 (60)
Patient Gender, n (%)
Female
45 (32)
28 (32)
8 (31)
7 (41)
Male
94 (68)
60 (68)
18 (69)
10 (59)
Patient Education, n (%)
Elementary (including 6th)
77 (55)
55 (63)
10 (38)
8 (47)
Middle School
26 (19)
16 (18)
6 (23)
2 (12)
High School
36 (26)
17 (19)
10 (39)
7 (46)
Patient Ethnicity, n (%)
Latinx
47 (34)
31 (35)
9 (35)
5 (29)
Non-Latinx, Racially Minoritized
16 (12)
10 (11)
3 (12)
2 (12)
Non-Latinx, white
76 (55)
47 (53)
14 (53)
10 (59)
Number of Kids in Home, n (%)
1 (patient only)
19 (14)
11 (13)
5 (19)
1 (6)
2 kids
52 (37)
32 (36)
11 (42)
7 (41)
3 kids
47 (34)
32 (36)
6 (23)
7 (41)
4+ kids
21 (15)
13 (15)
4 (15)
2 (12)
Breakdown of Kids in Home, n (%)
Younger kids in home (y/n)
78 (56)
54 (61)
9 (35)
13 (81)b
Older kids in home (y/n)
73 (53)
46 (52)
16 (61)
8 (47)
Caregiver Gender, n (%)
Female-identifying caregiver
128 (92)
84 (96)
23 (88)
14 (82)
Male-identifying caregiver
11 (8)
4 (4)
3 (12)
3 (18)
Primary Caregiver’s Marital Status, n (%)
Married
96 (69)
61 (69)
15 (58)
13 (76)
Not Married
43 (31)
27 (31)
11 (42)
4 (24)
Household Incomec, n (%)
< $18,745
36 (26)
23 (27)
10 (38)
1 (6)
$18,745 - $32,874
18 (13)
10 (12)
5 (19)
3 (19)
$32,875 - $48,999
13 (9)
6 (7)
1 (4)
5 (31)
$49,000 - $72,999
20 (14)
15 (18)
3 (12)
1 (6)
$73,000 - $126, 500
31 (22)
20 (23)
6 (23)
3 (19)
> $126,500
17 (12)
11 (13)
1 (4)
3 (19)
Household Composition, n (%)
One caregiver household
45 (32)
25 (28)
13 (50)
6 (35)
Two caregiver household
94 (68)
63 (72)
13 (50)
11 (65)
Abbreviations. M, mean; SD, standard deviation.
a
F (2, 130) = 3.83, p = 0.024; Tukey post-hoc analyses. Adolescents in the optimal adherence group were
significantly younger than those in the moderate adherence group, M diff= 1.83 years, p = 0.044.
b 2
𝑥 (1, 130) = 9.815, p = 0.007; chronically non-adherent patients were more likely to have younger children in
home.
c
Four families did not report on income. Full sample for income (n = 135), across the groups (n = 127).
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Table 2b. Baseline Demographic and Medical Characteristics of Adherent and Non-Adherent Trajectory Groups
Full sample (N = 131)
Latinx sample (n = 45)
Nonadherent
Group (n = 43)

Adherent
Group (n = 88)

Nonadherent
Group (n = 14)

Adherent
Group (n = 31)

non-Latinx, white (n = 71)
Nonadherent
Group (n = 24)

Adherent
Group (n = 47)

Patient Age Group, n (%)
Pre-adolescence (7-9.99)
8 (19)
38 (43)a
2 (14)
11 (36)
5 (21)
24 (51)b
Early-Middle adolescence (10-14.99)
17 (40)
30 (34)
6 (43)
10 (32)
9 (37)
14 (30)
Middle-Late adolescence (15-19)
18 (41)
20 (23)
6 (43)
10 (32)
10 (42)
9 (19)
Number of Young Children in Home, M (SD) 0.8 (1.0)
1.0 (1.0)
1.2 (1.1)
1.5 (1.1)
0.6 (0.8)
0.7 (0.9)
Study Group
Intervention, n (%)
19 (44)
48 (55)
7 (50)
14 (45)
8 (33)
26 (55)
Control, n (%)
24 (56)
40 (45)
7 (50)
17 (55)
16 (67)
21 (45)
Diagnosis duration (years), M (SD)
1.3 (0.3)
1.3 (0.4)
1.4 (0.3)
1.3 (0.3)
1.2 (0.4)
1.3 (0.4)
Dose (mg) baseline, M (SD)
102.8 (44.1)
77.7 (36.5)**
121.4 (55.3)
87.9 (40.8)*
93.5 (34.8)
72.3 (30.9)*
Dose (mg) 6mo, M (SD)
107.0 (50.9)
88.4 (37.1)*
126.9 (70.3)
94.4 (39.1)
93.1 (37.4)
84.2 (34.8)
Dose (mg) 15mo, M (SD)
125.8 (47)
91.7 (40.9)**
144.4 (57.0)
98.5 (40.2)*
106.9 (34.1)
83.8 (41.8)*
NOE (baseline), M (SD)
33.0 (12.9)
32.2 (13.4)
34.6 (14.7)
35.1 (15.7)
32.1 (12.6)
30.1 (11.8)
NOE (6mo), M (SD)
30.8 (13.1)
30.2 (13.7)
36.1 (14.2)
33.0 (14.4)
27.4 (11.5)
27.9 (13.9)
NOE (15mo), M (SD)
32.3 (13.8)
31.2 (14.9)
40.0 (15.7)
34.2 (15.7)
27.6 (11.3)
29.6 (15.5)
PT (baseline), M (SD)
45.7 (13.7)
46.4 (12.8)
49.8 (14.5)
49.4 (12.2)
44.0 (13.7)
44.3 (12.0)
PT (6mo), M (SD)
44.2 (14.4)
42.9 (13.8)
49.3 (14.5)
47.4 (13.7)
41.1 (13.8)
40.4 (13.2)
PT (15mo), M (SD)
43.4 (13.5)
42.8 (13.6)
50.2 (14.8)
48.3 (14.5)
40.1 (12.4)
40.2 (12.5)
POE (baseline), M (SD)
112.4 (15.5)
118.3 (13.3)*
109.5 (14.3)
118.6 (10.8)*
117.1 (12.4)
118.7 (15.4)
POE (6mo), M (SD)
113.2 (19.7)
117.1 (14.8)
111.2 (15.7)
111.9 (16.6)
116.9 (20.3)
120.1 (12.9)
POE (15mo), M (SD)
115.1 (16.1)
118.1 (14.6)
112.9 (15.4)
116.0 (15.8)
118.8 (14.3)
118.3 (15.2)
Intent (baseline), M (SD)
42.7 (5.7)
45.0 (4.5)*
41.4 (5.5)
44.6 (5.4)
44.5 (4.6)
45.6 (3.8)
Intent (6mo), M (SD)
44.2 (5.7)
44.7 (5.2)
42.9 (7.0)
43.3 (6.5)
45.1 (4.8)
45.9 (3.4)
Intent (15mo), M (SD)
43.8 (5.5)
44.8 (5.0)
41.5 (6.1)
44.0 (6.2)
45.3 (3.6)
45.7 (3.7)
PAC Frequency (baseline)
12.8 (9.9)
14.5 (10.1)
13.2 (5.7)
16.4 (9.9)
13.7 (12.2)
13.5 (10.7)
PAC Frequency (6mo)
11.5 (10.7)
13.7 (9.2)
16.0 (14.6)
13.9 (7.5)
10.5 (8.3)
13.4 (10.6)
PAC Frequency (15mo)
9.1 (8.3)
13.8 (10.8)*
13.3 (11.2)
15.6 (12.6)
7.7 (6.0)
13.3 (10.5)*
PAC-P Frequency (baseline)
13.4 (9.7)
17.1 (12.9)
20.2 (14.5)
21.2 (12.9)
10.5 (5.4)
14.9 (13.1)
PAC-P Frequency (6mo)
12.0 (11.9)
17.1 (13.1)*
20.6 (18.4)
23.1 (14.5)
8.3 (7.5)
14.1 (11.6)*
PAC-P Frequency (15mo)
13.0 (12.7)
15.3 (12.1)
24.3 (16.8)
18.5 (11.7)
7.1 (4.7)
15.1 (13.0)***
Abbreviations. n, number; %, percentage; M, mean; SD, standard deviation; mg, miligrams; mo, months; PAC, Parent-Adolescent Communication; PAC-P, ParentAdolescent Communication – Parent Report. Notes. * Significant at the 0.05 level (2-tailed); ** Significant at the 0.01 level (2-tailed); *** Significant at Bonferroni corrected
0.006 level (2-tailed).
a 2
χ (2, 131) = 8.85, p = 0.012
b 2
χ (2, 71) = 6.86, p = 0.03
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Table 3. Cronbach’s Alpha for Study Measures
Full sample
Baseline

Latinx

6 month

15 month

Baseline

BAMS (Young Child)

0.78

0.77

0.79

0.67

BAMS

0.73

0.84

0.79

0.74

B

C

A

Non-Latinx, white

6 month

15 month

Baseline

0.82

0.84

0.70

0.84

0.81

0.70

D

CDI

0.66

0.66

0.72

0.72

0.60

0.72

0.58

BDI

0.91

0.92

0.93

0.93

0.94

0.93

PAC Frequency Total

0.82

0.79

0.82

0.70

0.79

PAC-P Frequency Total

0.88

0.90

0.88

0.87

0.92

0.74

0.77

0.87

0.82
F

0.69

0.75

0.88

0.90

0.92

0.86

0.85

0.76

0.80

0.90

0.87

0.86

0.87

0.89

0.89

-

0.73

(error)

-

0.91

0.93

-b

PedsQL (Child)

0.87

0.89

0.88

0.89

0.86

0.76

0.85

0.90

0.91

PedsQL (Adolescent)

0.89

0.89

0.89

0.93

0.90

0.81

0.88

0.81

b

Parent PedsQL (Young Child)

0.84

0.51

-

0.52

Parent PedsQL (Child)

0.89

0.87

0.91

0.90

a

15 month

PedsQL (Young Child)

G

b

E

6 month

0.90
H

a

b

b

(error)

-

0.89

0.72

-b

0.87

0.85

0.90

0.88

0.93

Parent PedsQL (Adolescent)
0.93
0.92
0.95
0.95
0.95
0.97
0.88
0.89
0.88
Abbreviations. BAMS, Beliefs about Medication Scale; CDI, Children’s Depression Inventory; BDI, Beck Depression Inventory; PAC, Parent-Adolescent
Communication; PAC-P, Parent-Adolescent Communication – Parent; PedsQL, Pediatric Quality of Life measure.
a
Cronbach’s alpha value indicated negative average covariance. This violates reliability model assumptions.
b
All youth who were 7 years old at baseline aged up to the next form by the 15 month data collection (n = 0).
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Table 4. Group-Based Trajectory Modeling: Weekly Adherence (N = 131)
Adherence Group Trajectory

Parameter

Estimate (Std. Err.)

t

p

Intercept

96.32 (0.83)

115.67

< .001

Time

-0.10 (0.06)

-1.67

0.09

Intercept

67.58 (1.59)

42.61

< .001

Time

-0.006 (0.002)

-3.14

< .001

Intercept

62.69 (1.93)

32.50

< .001

Time

-2.82 (0.15)

-18.67

< .001

Optimal Adherence

Moderate Adherence

Chronic Nonadherence
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Table 5. Medical, Individual- and Family- Level Factors Across Adherence Groups (N = 131)
Optimal Adherence
Group (n =88)

Moderate Adherence
Group (n = 26)

Chronically
Non-adherent
Group (n = 17)

Dose (mg) baseline, M (SD)
Dose (mg) 6mo, M (SD)
Dose (mg) 15mo, M (SD)

77.7 (36.5)a
88.4 (37.1)a
91.7 (40.9)a

114.2 (44.9)a
118.4 (55.1)a
136.1 (47.1)a

85.3 (3.6)b
89 (38.7)
111.5 (45.2)

CDI raw (baseline), M (SD)
CDI raw (6mo), M (SD)
CDI raw (15mo), M (SD)
Clinically Significant BDI (baseline), n (%)
Clinically Significant BDI (6mo), n (%)
Clinically Significant BDI (15mo), n (%)
NOE (baseline), M (SD)
NOE (6mo), M (SD)
NOE (15mo), M (SD)
PT (baseline), M (SD)
PT (6mo), M (SD)
PT (15mo), M (SD)
POE (baseline), M (SD)
POE (6mo), M (SD)
POE (15mo), M (SD)
Intent (baseline), M (SD)
Intent (6mo), M (SD)
Intent (15mo), M (SD)

1.3 (1.5)
1.4 (1.6)
1.3 (1.9)
6 (46.2)
10 (66.7)
8 (61.5)
32.2 (13.4)
30.2 (13.7)
31.2 (14.9)
46.4 (12.8)
42.9 (13.8)
42.8 (13.6)
118.3 (13.3)c
117.1 (14.8)
118.1 (14.6)
45 (4.5)
44.7 (5.2)
44.8 (5)

2.0 (2.6)
1.7 (2.0)
1.4 (1.8)
5 (38.5)
3 (20.0)
4 (30.8)
36.2 (12.9)
32.7 (13.3)
33.2 (14.5)
48.5 (12.6)
46 (14.3)
43.1 (12)
110.3 (15.2)c
113.9 (15.5)
113.1 (14.5)
42.9 (5.6)
43.5 (5.6)
43.1 (5.4)

1.1 (2.4)
0.9 (2.0)
0.9 (2.4)
2 (15.4)
2 (13.3)
1 (7.7)
28.1 (11.5)
28 (12.6)
31.1 (13.3)
41.5 (14.5)
41.5 (14.5)
43.8 (15.9)
115.6 (15.9)
112.1 (25.1)
117.7 (18.2)
42.6 (6.1)
45.2 (5.7)
44.8 (5.7)

13.0 (11.4)
12.5 (7.5)
PAC Frequency (baseline)
14.5 (10.1)
13.7 (9.2)
13.1 (12.4)
9.2 (7.5)
PAC Frequency (6mo)
d
13.8
(10.8)
11.2
(9.6)
6.1 (4.8)d
PAC Frequency (15mo)
13.1 (11.5)
13.8 (5.8)
PAC-P Frequency (baseline)
17.1 (12.9)
17.1 (13.1)
13.9 (14.4)
9.3 (6.6)
PAC-P Frequency (6mo)
15.3
(12.1)
13.5
(14.3)
12.4 (10.6)
PAC-P Frequency (15mo)
1.5 (0.6)
1.5 (0.6)
PAC Mean Conflict (baseline)
1.4 (0.6)
1.5 (0.5)
1.6 (0.7)
1.4 (0.3)
PAC Mean Conflict (6mo)
1.6
(0.7)
1.6
(0.8)
1.7 (0.6)
PAC Mean Conflict (15mo)
1.7 (0.7)
1.7 (0.6)
PAC-P Mean Conflict (baseline)
1.4 (0.5)
1.7 (0.8)
1.7 (0.8)
1.4 (0.4)
PAC-P Mean Conflict (6mo)
1.7
(0.8)
1.6
(0.8)
1.4 (0.5)
PAC-P Mean Conflict (15mo)
Abbreviations. mg; milligrams; M, mean; SD, standard deviation; CDI, Children’s Depression Inventory; BDI,
Beck Depression Inventory; QoL, quality of life; NOE, negative outcome expectancy; PT, perceived threat; POE,
positive outcome expectancy; PAC, Parent-Adolescent Communication; PAC-P, Parent-Adolescent Communication
– Parent.
a
Tukey post-hoc analyses indicated 6-MP dosage was significantly lower for those in the optimal adherence group
compared to those in the moderate adherence group at baseline, 6mo, and 15mo (p < 0.05).
b
Tukey post-hoc analyses also indicated 6-MP dosage was significantly higher for those in the moderate adherence
group compared to those in the chronically non-adherent group at baseline (p < 0.05).
c
Tukey post-hoc analyses indicated that youth in the optimal adherence group reported higher positive outcome
expectancy than those in the moderate adherence group at baseline (p = 0.031).
d
Tukey post-hoc analyses indicated that youth in the optimal adherence group reported more frequent
communication at 15 months than those in the chronically non-adherent group (p = 0.017).
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Table 6. Correlations Between Dependent Variable (Adherent vs. Non-Adherent Group) and Potential Baseline Covariates
Study
Group

Age
Group

Adolescent
Gender

Ethnicity
Race

Household
Composition

Maternal
Education

Household
Income

Age Group

0.06

-

Adolescent Gender

0.04

.17*

-

Race and Ethnicity

-0.01

0.11

0.02

-

Household Composition

-.17*

-0.05

-0.09

-.34**

-

Maternal Education

-0.001

-0.04

0.03

-.59**

0.17

-

Household Income

-0.05

-0.12

-0.06

-.59**

.46**

.65**

-

Time since dx

0.13

-0.01

-.38**

0.10

-0.05

-0.14

-0.02

Diagnosis
duration

-

Adherence Group
-0.01
-.26**
-0.03
0.03
0.14
-0.06
0.07
0.05
Abbreviations. mg, milligrams; dx, diagnosis; Notes. *Correlation is significant at the 0.05 level (2-tailed); ** Correlation is significant at
the 0.01 level (2-tailed).
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Table 7. Logistic Regression Models Predicting Adherence Group Membership Outcomes (Aim 2a)
Child-Reported Communication Model

Caregiver-Reported Communication Model

χ2

χ2

Odds Ratio

95% CI

p

Odds Ratio

95% CI

p

Time

5.08

1.00

1.0 - 1.0

0.02

2.31

1.00

1.0 - 1.0

0.13

6MP Dosage

5.25

1.00

1.0 - 1.0

0.02

4.09

1.00

1.0 - 1.0

0.04

Age Group

7.41

0.25

0.09 - 0.68

<0.01

7.08

0.24

0.08 - 0.68

<0.01

# of Younger Kids in Home

0.46

0.86

0.57 - 1.32

0.50

0.92

0.80

0.52 - 1.26

0.34

NOE

1.80

1.00

1.0 - 1.0

0.18

1.95

1.00

1.0 - 1.0

0.16

POE

3.08

1.00

1.0 - 1.0

0.08

5.16

1.00

1.0 - 1.0

0.02

Intent

3.40

1.00

1.0 - 1.0

0.07

1.70

1.00

1.0 - 1.0

0.19

1.45
1.00
1.0 - 1.0
0.23
2.47
1.00
1.0 - 1.0
0.12
Communication Frequency
Abbreviations. 6MP, 6-mercaptopurine; #, number; NOE, Negative Outcome Expectancy subscale; POE, Positive Outcome Expectancy. Notes. Age group and
number of younger kids in home utilized baseline data; time, 6MP dosage, NOE, POE, Intent, Communication Frequency utilized baseline, 6 month, and 15
longitudinal data.
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Table 8. Differences in Independent Variables by Age Group
Pre-adolescence
(7-10 years)

Early-Middle
Adolescence
(10-15 years)

Middle-Late
Adolescence
(15-19 years)

Dosage, mg (Baseline)
Dosage, mg (6 mos)
Dosage, mg (15 mos)

71.32 (32.74)
76.33 (25.83)
82.07 (30.12)b

87.92 (38.91)
93.42 (42.85)
104.86 (48.11)

108.54 (46.30)a
121.25 (48.22)a
136.16 (42.40)a

# of Younger Kids in Home (Baseline)
NOE (baseline)
NOE (6 mos)
NOE (15 mos)
POE (baseline)
POE (6 mos)

0.82 (0.90)
31.41 (13.08)
28.98 (13.93)
30.40 (14.42)
118.92 (15.20)
117.60 (13.32)

1.04 (0.92)
29.63 (11.67)
29.85 (12.33)
30.40 (14.42)
115.54 (13.01)
115.00 (20.47)

0.75 (1.06)
37.05 (13.59)c
33.70 (13.74)
30.40 (14.42)
114.56 (14.89)
116.03 (14.4)

POE (15 mos)
Intent (baseline)
Intent (6 mos)
Intent (15 mos)
Child Total Communication (baseline)

117.02 (15.40)
43.84 (5.16)
44.00 (5.83)
43.72 (5.69)
15.82 (11.27)

117.21 (16.14)
44.63 (4.04)
45.35 (4.25)
44.64 (4.79)
13.54 (8.93)

116.35 (15.67)
43.76 (6.32)
44.80 (5.67)
45.26 (5.14)
12.93 (10.9)

Child Total Communication (6 mos)
Child Total Communication (15 mos)
Caregiver Total Communication (baseline)
Caregiver Total Communication (6 mos)
Caregiver Total Communication (15 mos)

15.81 (11.47)
15.70 (10.88)d
16.69 (12.75)
17.95 (14.02)
16.65 (12.21)

11.78 (7.76)
10.49 (9.43)
14.05 (10.98)
13.10 (10.82)
12.67 (12.39)

11.68 (8.94)
8.82 (8.11)
18.40 (13.12)
15.13 (12.69)
13.24 (11.35)

Abbreviations. mg, milligrams; mos, months; #, number; NOE, Negative Outcome Expectancy subscale; POE,
Positive Outcome Expectancy.
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Table 9. Logistic Regression Models Predicting Adherence Group Membership Outcomes (Aim 3)
Total HRQoL
Child-Reported Communication Model

χ2

Odds Ratio

95% CI

Total HRQoL
Caregiver-Reported Communication Model
p

χ2

Odds Ratio

95% CI

p

Time

3.3

1

1.0 - 1.0

0.07

4.22

1

1.0 - 1.0

0.04

6MP Dosage

4.4

1

1.0 - 1.0

0.04

4.37

1

1.0 - 1.0

0.04

Age Group

5.25

0.28

0.09 - 0.83

0.02

5.25

0.28

0.09-0.83

0.02

# of Younger Kids

0.64

0.84

0.55 - 1.29

0.42

0.64

0.84

0.55 - 1.29

0.42

POE

4.37

1

1.0 - 1.0

0.04

4.71

1

1.0 - 1.0

0.03

Total PedsQL

0.33

1

1.0 - 1.0

0.57

0.29

1

1.0 - 1.0

0.59

Nausea HRQoL
Child-Reported Communication Model

χ2

Odds Ratio

95% CI

Nausea HRQoL
Caregiver-Reported Communication Model
p

χ2

Odds Ratio

95% CI

p

Time

2.44

1

1.0 - 1.0

0.12

3.47

1

1.0 - 1.0

0.06

6MP Dosage

4.17

1

1.0 - 1.0

0.04

4.43

1

1.0 - 1.0

0.04

Age Group

5.96

0.26

0.09 - 0.76

0.01

5.96

0.26

0.09-0.76

0.01

POE

3.79

1

1.0 - 1.0

0.053

4.28

1

1.0 - 1.0

0.04

Nausea PedsQL
31
1
1.0 - 1.0
0.58
1.14
1
1.0 - 1.0
0.29
Abbreviations. HRQoL, Health-Related Quality of Life; CI, confidence; 6MP, 6-mercaptopurine; #, number; POE, positive outcome expectancy; PedsQL,
Pediatric Quality of Life measure. Notes. Age group and number of younger kids in home utilized baseline data; time, 6MP dosage, Total PedsQL utilized
baseline, 6 month, and 15 longitudinal data.
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Table 10. Independent Variable Included in mixed ANOVAs
Child Total QoL

Caregiver Total QoL

Child Nausea QoL

Caregiver Nausea QoL

Timepoint

x

x

x

x

Adherence Group

x

x

x

x

Income

x

x

Maternal Education

x

x

Gender
Age Group
Ethnicity + Race

a

x
x

x

x

x

x

x

Race
# of People in Home

x
x

Study Group

x
b

House Composition
x
Abbreviations. QoL, Quality of Life; #, number.
Notes. Variables included in each model were significantly correlated (p < 0.05) at least at one timepoint (0, 6, 15
months). Baseline demographic data was utilized for income, maternal education, gender, age group, ethnicity +
race, race, # of people in the home, study group, and house composition.
a
Variable capturing both ethnicity and race. Three possible categories: (1) Latinx, (2) non-Latinx racially
minoritized, (3) non-Latinx white.
b
Composition of caregivers (i.e., one or two parent household).
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Figure 1. Group-based trajectories for adherence, measured by electronic monitoring, from
baseline to 15 months (N = 131).
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Figure 2. Percentage of Youth in Age Groups (within Adherence Group)

Figure 3. Dosage (mg) Across Adherence Groups
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Figure 4. Negative Outcomes Expectancy Across Adherence Groups

Figure 5. Positive Outcomes Expectancy Across Adherence Groups
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Figure 6. Intent Across Adherence Groups

Figure 7. Child-Reported Total Communication Frequency Across Adherence Groups
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Figure 8. Caregiver-Reported Total Communication Frequency Across Adherence Groups

Figure 9. Caregiver-Reported Average Communication Intensity Across Adherence Groups
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Figure 10. Child-Reported Total HRQoL Across Adherence Groups
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Figure 12. Child-Reported Nausea HRQoL Across Adherence Groups
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Figure 13. Caregiver-Reported Nausea HRQoL Across Adherence Groups
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Appendix A. Interviewer Instructions for PedsQL Young Child (5-7) Report

PedsQL™
Cancer Module
Version 3.0
YOUNG CHILD REPORT (ages 5-7)
Instructions for interviewer:
I am going to ask you some questions about things that might be a problem for some
children. I want to know how much of a problem any of these things might be for you.
Show the child the template and point to the responses as you read.
If it is not at all a problem for you, point to the smiling face
If it is sometimes a problem for you, point to the middle face
If it is a problem for you a lot, point to the frowning face
I will read each question. Point to the pictures to show me how much of a problem it is for you.
Let’s try a practice one first.

Is it hard for you to snap your fingers

Not at all

Sometimes

A lot

☺





Ask the child to demonstrate snapping his or her fingers to determine whether or not the question
was answered correctly. Repeat the question if the child demonstrates a response that is different
from his or her action.
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Appendix B. Interviewer Instructions for PedsQL Young Child (5-7) Report
Instructions:
Think about how you have been doing for the past one month. Please listen carefully to each sentence and tell me how much of a
problem this is for you.
After reading the item, gesture to the template. If the child hesitates or does not seem to understand how to answer, read the response
options while pointing at the faces.

How much of a problem is this for you?

Not at all

Sometimes

A lot

☺
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Appendix C. Original Study Document Regarding Changes to Beliefs about Medication Measure
Administration for Younger Participants (<11years)

Notes Regarding OPTIMAL Forms for Younger Participants
We have noticed at our site that our younger study participants are having difficulty both reading
and understanding some of the assessments that we administer.
In particular, it seems they struggle more with the SPSI and the BAMS. For this reason, it will be
beneficial to administer these questionnaires in an interview format (read questions and write
down their responses) for participants under 11 years old.
The language seems to be advanced for our younger participants, so it is also a good idea to
paraphrase some of the more complex questions.
The following are some specific questions and examples of how to paraphrase them from the
BAMS:
•

Q. 29 “Other people with my illness get very sick even if they take their medicine the
way the doctor says they should.” Paraphrase, “Other kids with cancer get very sick even
when they take their medicine the right way.”

•

Q. 30 “I have a lot to gain from taking my medicine the way the doctor says I should.”
Paraphrase: “It will be good for me to take my medicine like the doctor says I should.”

•

Q. 35 “If I take my medicine the way the doctor says I should, it will keep me from
getting sicker.” Paraphrase: “I won’t get sicker if I take my medicine like the doctor
says.”
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Appendix D. Visual Diagram Used with Younger Participants (<11years) for Beliefs about Medicine Scale (BAMS) – Child Version

Visual Diagram to be used during Interview Administration
PLEASE RATE HOW MUCH YOU AGREE ☺ OR DISAGREE  WITH EACH STATEMENT USING
THE FOLLOWING RATING SCALE:


1
Disagree a Lot

2
Disagree Mostly




3
Disagree a Little
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4
Don’t Agree
nor Disagree

☺
5
Agree a Little

☺
6
Agree Mostly

☺
7
Agree a Lot
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